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ABSTRACT 
Oxidative stress is associated with several diseases, either as a cause or a consequence. 
Chronic kidney disease (CKD) is one example of a disease in which elevated levels of 
oxidative stress are frequently reported. Oxidative stress, inflammation and 
malnutrition are risk factors that contribute to an increased risk for cardiovascular 
disease and a higher morbidity and mortality in CKD patients. In addition, oral 
complaints such as periodontitis and mouth dryness are recurrently reported. 
Furthermore, oxidative stress can also be induced by exogenous sources such as toxic 
agents in our environment. Nanoparticles, which are increasingly used in the society, 
can potentially cause adverse health effects with oxidative stress as a proposed 
underlying toxic mechanism. Yet, nanoparticles offer tremendous possibilities for the 
society, not least within biomedical applications. 
 
The aim of Study I in this thesis was to investigate the effects of kidney disease on 
DNA damage and oxidative stress in the salivary glands. The comet assay was used for 
the analysis and the results showed that the DNA damage in predialysis patients (CKD 
patients not yet on dialysis) was higher compared to controls as well as CKD patients 
on dialysis. The dialysis patients showed lower levels of DNA damage compared to the 
controls. There were no differences between the groups regarding the oxidative DNA 
damage. The inflammation and uremic markers were elevated in all CKD patients 
compared to the controls. The results suggest that the DNA in salivary glands are 
affected differently compared to in circulating blood cells that have been studied in 
previous studies in CKD patients, potentially due to upregulated DNA repair and 
antioxidative mechanisms in the peripheral tissue. 
 
The aim of Study II was to examine health effects of dietary supplementation with an 
extract of sea buckthorn rich in antioxidants and fatty acids. The patient group was 
dialysis patients and the main outcomes were DNA damage and oxidative stress in the 
salivary glands, as well as saliva production. No significant effects on DNA damage, 
oxidative DNA damage or saliva production were observed in this crossover 
intervention study (2 × 8 weeks).  
 
A further aim of the thesis was to investigate the toxicity of nanoparticles in vitro. A 
wide range of nano- and microsized particles was screened for cytotoxicity. Cu- and 
Zn-based (Cu, CuO, CuZn, Zn, ZnO) nanoparticles were found to be particularly 
cytotoxic. The Cu-based particles were cytotoxic in a size-dependent manner. 
Furthermore, the toxicity was found to be dependent on the type of cell investigated. 
 
In Study III the aim was to elucidate the toxic mechanisms of Cu-based (Cu and CuO) 
nanoparticles. The studies were performed in a leukemic cell line, and the results 
showed that the Cu nanoparticles were most cytotoxic, followed by CuCl2 and lastly 
CuO nanoparticles. The Cu nanoparticles induced high levels of oxidation in an 
acellular method, as well as slightly increased levels of intracellular reactive oxygen 
species (ROS) and oxidative DNA damage in the cells. CuO nanoparticles did not 
induce acellular ROS, and the induction of intracellular ROS and DNA damage was 
limited. Differences in metal release processes may explain the differences in toxicity 
modes between Cu and CuO nanoparticles. 
 
In Study IV, the application of nonporous and mesoporous amine-modified silica 
nanoparticles as plasmid delivery vectors was explored. Both of the silica particles 
were found to be biocompatible in the human breast carcinoma cell line that was 
studied. Nonporous particles were more efficient in the delivery of the plasmids. 
Addition of serum in the cell medium increased the delivery efficiency as well as 
restricted the toxicity. 
 
In conclusion, the studies in this thesis indicate that the DNA in the oral tissue is less 
affected by kidney disease and the dialysis treatment compared to circulating blood 
cells. Dietary supplementation with a berry extract containing fatty acids and 
antioxidants appears to not affect the levels of DNA damage and oxidative damage in 
the oral tissue. Moreover, certain nanoparticles are toxic, and the toxicity is dependent 
on several factors including the chemical composition, particle size and dissolution. 
Concurrently, some nanoparticles, including silica nanoparticles, offer exciting 
possibilities to be used as platforms for biomedical applications. Taken together, further 
investigations on both toxicity and application of nanomaterials are required to avoid 
negative health effects as well as to embrace their beneficial use. 
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1 INTRODUCTION 
Our health can be affected by factors in the environment, life style and dietary habits, 
as well as by disease. Exposure to toxic agents present in the air, soil, food and water 
can damage our cells and lead to disease development, further affecting our life span 
and life-quality. Some toxic agents are linked to the generation of reactive oxygen 
species (ROS), which have the potential to damage cellular molecules. ROS are also 
continuously formed during normal cell metabolism. Cells and organisms have 
therefore evolved an extensive antioxidative system. Oxidative stress, a condition of 
an imbalance between oxidative and antioxidative processes, can result in damage to 
the DNA, proteins and lipids in cells. Cancer, cardiovascular disease, diabetes, 
kidney disease, Parkinson’s and Alzheimer’s disease are all examples of diseases 
associated with oxidative stress, either as a cause or as a consequence of the disease1. 
In agreement with the free radical theory of ageing, oxidative stress is also considered 
to play an important role in normal ageing processes2. 
 
The antioxidative system includes both endogenous antioxidants as well as 
antioxidants derived from diet. As some vitamins and other micronutrients have 
antioxidative properties, there is a great interest in dietary supplementation containing 
these substances, with the aim to improve the health and to prevent disease and 
ageing. The effects of these supplements are however unclear. Studies on dietary 
supplementation have not consistently shown beneficial health effects; several studies 
show lack of effects and some studies even show harmful effects3. 
 
The first part of this thesis is based on two human studies with chronic kidney disease 
(CKD) patients (Study I and Study II). CKD is a disease with a progressive loss of 
renal function, resulting in an augment of uremic toxins in the blood. Renal disease is 
associated with elevated levels of oxidative stress and inflammation, and increased 
risk for cardiovascular disease4. In addition, CKD patients also often report impaired 
oral health5. CKD is an increasing worldwide public health problem, with a global 
prevalence of 8–16%6.  
 
The aim of Study I was to assess the levels of DNA damage and oxidative stress in 
the salivary glands, as well as the potential correlation with saliva production, 
inflammation and uremic markers in CKD patients. The aim of Study II was to 
evaluate the effects of dietary supplementation with a sea buckthorn extract on the 
levels of DNA damage, oxidative stress, saliva production, inflammation and uremic 
markers in CKD patients. Sea buckthorn has been attributed with beneficial health 
effects including antioxidative, antiproliferative and anti-inflammatory effects, as 
well as improved function of mucous membranes7-9. Thus, it was hypothesised that 
the sea buckthorn extract could improve oral health, potentially by decreasing DNA 
damage and oxidative DNA damage in the salivary glands, as well as improve the 
saliva production. 
 
Study I and Study II were previously summarised in the licentiate thesis “Assessment 
of DNA damage, oxidative stress and inflammation in chronic kidney disease 
patients – and a clinical study of a dietary supplement”10. While the main literature 
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review and the results and discussion on chronic kidney disease, dietary 
supplementation and sea buckthorn originate from the licentiate thesis, an updated 
version is presented in this thesis. 
 
Exposure to nanomaterials is an environmental factor that could have impact on our 
health. The rapid development of nanotechnology enables engineering of 
nanomaterials with unique properties that make them attractive for usage within 
electronics, medicine, inks and cosmetics among other areas. The increased 
production and spread in the society can potentially increase the human exposure to 
nanomaterials, e.g. from the air, at working places or from consumer products. The 
exposure to nanomaterials may pose increased health risks as the small size of 
nanomaterials can implicate alterations in the interactions with biological systems, 
including the exposure and translocation routes, cellular uptake and toxic 
mechanisms11,12. To ensure a safe development of nanoproducts and nanomedicine, 
and to protect humans and the environment against adverse effects, there is a great 
need for a deeper understanding on how nanoparticles interact with biological 
systems.  
 
The second part of this thesis is based on two in vitro studies on interactions of 
nanoparticles with human cells. The aim was to identify particularly toxic particles, 
to elucidate the toxic mechanisms of Cu-based (Cu and CuO) nanoparticles, as well 
as to investigate the biocompatibility and potential use of silica nanoparticles for gene 
delivery. A range of particles was screened for cytotoxicity, while cell-type specific 
cytotoxicity was investigated for a selection of the particles. The particularly toxic 
Cu-based nanoparticles were selected for further studies on toxic mechanisms in 
Study III. In Study IV, the possibility to use silica nanoparticles for gene delivery was 
explored. Their biocompatibility as well as their efficiency in delivering plasmid 
DNA in a breast carcinoma cell line was investigated. 
 
As oxidative stress is involved in CKD as well as in the toxicity of nanoparticles, the 
next sections will therefore introduce oxidative stress, DNA damage, CKD, sea 
buckthorn, nanotechnology and nanotoxicology. 
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2 OXIDATIVE STRESS 
All aerobic organisms require, as the name indicates, oxygen (O2) for an efficient 
energy production. Energy is produced through the electron transport chain that takes 
place in the mitochondria in eukaryotic cells. Oxygen from the air is in humans 
transported via the lungs and blood to tissues and cells by a protein called 
haemoglobin. This transport is mediated by the haem groups of the protein, where the 
Fe2+ is oxidised to Fe3+ upon oxygen binding. In the cell, the electron donors NADH 
and FADH2 deriving from metabolic pathways, are used for the step-wise reduction 
of O2 that forms H2O as the final end product, as seen in Figure 1. These electron 
transfers build up a proton gradient across the inner mitochondrial membrane, which 
can generate adenosine-5’-triphosphate (ATP), the energy source of the cell. The 
redox reactions taking place in the mitochondria are tightly controlled by specific 
enzymes. Despite the control, electrons are occasionally slipping which can lead to 
the formation of ROS. The mitochondria are considered to be the major endogenous 
source of ROS13. Moreover, ROS can also be produced by the cell as a part of its 
pathogen defence as well as for cell signalling. In addition to the endogenous sources 
of ROS, environmental factors including radiation or exposure to toxic compounds 
such as tobacco smoke, diesel exhaust, ozone or nanoparticles, can induce the 
formation of ROS in cells. 
 
 
 
 
Figure 1. Electron transfers during the step-wise reduction of O2 to H2O taking place in the 
mitochondria. 
 
The term ROS includes both radicals, i.e. species with one or more unpaired 
electrons in their atomic or molecular orbitals, and non-radical oxygen species. 
Examples of ROS that are formed in the cell are superoxide (O2•-), hydrogen 
peroxide (H2O2) and the hydroxyl radical (HO•). Some of their cellular origin and 
defence are listed in Table 1. Molecular oxygen at ground state (O2) can be classified 
as a free radical with two unpaired electrons (i.e. a diradical) with parallel spins, but 
the reactivity is limited due to spin restrictions. Upon the addition of one electron, the 
superoxide anion O2•- is formed, which is a free radical with one unpaired electron 
that reacts poorly with biomolecules in aqueous solutions1. Nevertheless, O2•- can 
cause cellular damage by reacting with other species such as nitric oxide and form 
peroxynitrite, or it can oxidise Fe-S clusters in enzymes resulting in enzyme 
inactivation14. Phagocytic cells produce O2•- by the enzyme NADPH oxidase upon 
the activation by foreign substances. Dismutation of O2•- generates H2O2, which is a 
relatively weak oxidant. However, H2O2 can be cytotoxic and inactivate enzymes15. 
In addition, H2O2 is a potential source of the hydroxyl radical HO•, which is 
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generated upon the reaction with transition metals (e.g. Fe, Cu) in the Fenton reaction 
[1].  
 
 
The hydroxyl radical is extremely reactive and it can oxidise any cellular 
macromolecule close to its formation site, inducing radical chain reactions1. The rate 
of reaction is often only limited to the rate of diffusion of the reactants.  
 
Other central ROS are ozone (O3), singlet oxygen (1O2), hypochlorous acid (HOCl) 
and peroxyls (R-OO•). Reactive nitrogen species (RNS), including nitric oxide 
(NO•), nitrogen dioxide (NO2•) and peroxynitrite (ONOO-) are also important 
sources of oxidative stress in cells. 
 
Table 1. Examples of reactive oxygen and nitrogen species, and their cellular origin and defence.  
ROS/RNS Origin Defence 
Superoxide (O2•-) Leakage from the electron 
transport chain, 
NADPH oxidase, xanthine 
oxidase 
Superoxide dismutase 
Hydrogen peroxide (H2O2) Superoxide dismutase, 
NADPH oxidase 
Catalase, glutathione, 
peroxidase, peroxiredoxin 
Hydroxyl radical (OH•) Fenton reactions 
 
Sequestering of metal ions, 
e.g. transferrin and 
metallothionein   
Nitric oxide (NO•) Nitric oxide synthase Glutathione 
 
 
ROS are, as mentioned above, important for several redox reactions in the cells, in 
the immune system, for cell signalling, cell growth and differentiation. Concurrently, 
ROS also present a threat to the cell, as they can oxidise and damage cellular 
macromolecules. The intracellular environment is generally highly reduced. As a 
consequence of the aerobic respiration, aerobic cells are constantly exposed to ROS, 
and have therefore evolved an antioxidative system for counterbalance. The balance 
between the oxidative and the antioxidative processes is important for maintaining 
the appropriate redox state necessary for normal cell growth and proliferation, as 
depicted in Figure 2. The term oxidative stress was formulated by Helmut Sies in 
1985, and it describes the situation when there is a disturbance in the balance 
between oxidants and antioxidants, with the former overwhelming the latter16.  
 
Fe2+ + H2O2   →  Fe3+ + OH- + HO•     [1] 
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Figure 2. A balance between the oxidative and antioxidative processes in a cell is necessary for normal 
cell growth and proliferation. Excess levels of oxidants, or decreased levels of antioxidants, can cause 
damage to cellular macromolecules, potentially contributing to ageing processes or disease 
development.  
 
The redox state (the relation between oxidative and reductive processes) in a 
biological system is dynamic; it can shift upon changes in the environment. To a 
certain extent, cells and organisms can make adaptations to increased oxidative 
processes by regulating the activity of specific genes and enzymes important for the 
antioxidative defence. Transcription factors such as nuclear factor-κB (NF-κB) and 
activator protein-1 (AP-1) are regulated by the redox state in the cell17. Increased 
oxidative stress can promote signals for senescence and programmed cell death 
(apoptosis), and also lead to necrosis. 
 
 
2.1 OXIDATIVE DAMAGE 
ROS can cause oxidative damage to the DNA, proteins and lipids. This can lead to 
mutations in the genome or dysfunctions of the molecules, possibly leading to cancer, 
cell injury or cell death. This thesis is focused on damage to the DNA.  
 
2.1.1 DNA damage 
Our genetic information is stored in DNA, which is a molecule that is built up by four 
types of subunits; the nucleotides. Each nucleotide is composed of a five-carbon 
sugar, a phosphate group and one of the four bases adenine (A), cytosine (C), guanine 
(G) or thymine (T). Base pairing with hydrogen bonds between G and C, and T and 
Normal cell growth 
and proliferation 
Oxidants 
ROS, RNS 
 Antioxidants 
SOD, catalase, 
peroxidase, 
glutathione, vit C,     
vit E, transferrin 
Oxidative damage 
to DNA, proteins 
and lipids 
Ageing Disease 
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A connect two sugar-phosphate backbones, forming the double-stranded DNA 
molecule, depicted in Figure 3. 
 
 
Figure 3. DNA molecule illustrated with PyMOL18, courtesy Dr Arzu Uyar. 
 
The DNA is, like other biomolecules, subject to damage and instability. The integrity 
of the genome is continuously compromised, both by spontaneous modifications and 
by modifications induced by exogenous factors19,20. The damage can be induced by 
oxidation, hydrolysis, alkylation and ionising radiation. The major forms of DNA 
alterations include single and double strand breaks, base lesions, cross-links, base 
misincorporations, bulky adducts and modifications of the sugar backbone. Cellular 
responses to DNA damage include the activation of DNA repair, changes in the gene 
transcription, triggering of apoptosis or cell cycle arrest21. Failure in the cellular 
response may lead to mutations, i.e. permanent changes in the DNA sequence, and 
subsequent loss of cellular regulation, potentially leading to cancer development.  
 
All four bases and the sugar backbone of the DNA can be damaged by oxidation. 
Guanine has the lowest redox potential of the bases and is therefore the most readily 
oxidised base22. One of the most studied DNA oxidation product is 8-oxo-dG, which 
is formed after oxidation at the 8th position of dG (2´deoxy-guanosine)23, as shown in 
Figure 4.  
 
 
 
Figure 4. Oxidation of dG at the 8th position generates 8-OH-dG and 8-oxodG. 
 
The oxidised form of guanine can assume syn conformation which allows base 
pairing with adenine, causing a transversion of G:C to T:A during the replication24.  
8-oxodG is a common biomarker of oxidative stress and, due to its pro-mutagenic 
property, it is also a potential biomarker of carcinogenesis25. 8-oxodG and other 
DNA oxidation products can be detected and analysed by the comet assay, as 
described in section 7.1. As 8-oxodG is excreted in the urine, measurement of urinary 
levels of 8-oxodG is also a commonly used method to assess oxidative stress26. 
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2.1.2 DNA repair  
To counteract the constantly occurring DNA damaging processes, cells have evolved 
an extensive DNA repair system. The system consists of an ensemble of enzymes 
acting with different mechanisms and pathways depending on the type of damage. 
There are excision repair systems by which the damage is removed, mismatch repair 
systems that correct bases that have been misincorporated during the replication, and 
homologous and non-homologous recombination systems that repair double strand 
breaks. 
 
Base excision repair is the most common repair process for damaged bases, including 
8-oxoG. Damaged bases are recognised by glycosylases that remove the base via 
hydrolysis of the N-glycosyl bond between the sugar and the base, thus creating an 
abasic site. At this apurinic or apyrimidinic (AP) site, endonuclease or lyase activity 
creates a gap in the DNA backbone, which the DNA polymerase can fill with the 
appropriate nucleotide. The repair pathway is completed by ligase activity and 
sealing of the DNA. Human 8-oxoG DNA glycosylase (hOgg1) is an enzyme with 
both glycosylase and lyase activity, responsible for the removal of oxidised bases, 
including 8-oxoG27. Formamido pyrimidine DNA glycosylase (FPG) is the 
corresponding enzyme in Escherichia coli, and is often utilised to quantify oxidised 
DNA lesions in DNA analysis, including in the comet assay28. 
 
Bulky adducts, including pyrimidine dimers formed e.g. upon exposure to UV-light, 
are removed by nucleotide excision repair systems. This system recognises the 
damage and cuts the phosphodiester bonds via hydrolysis on both sides of the adduct, 
releasing an oligomer containing 24–32 nucleotides29. The gap in the DNA strand is 
subsequently filled and the nicks are ligated by DNA polymerase and DNA ligase. 
 
 
2.2 ANTIOXIDATIVE DEFENCE 
Regulation of the intracellular redox state is necessary for normal cellular function 
and protection of the biomolecules from damage. Cells have an extensive 
antioxidative system including mechanisms to prevent the formation of ROS, 
neutralise or remove ROS, as well as to repair the oxidative damage (e.g. the DNA 
repair, as described in section 2.1.2). The antioxidative system consists of a variety of 
enzymes, proteins and low molecular weight molecules such as glutathione and 
certain dietary antioxidants. 
 
2.2.1 Antioxidant enzymes and proteins 
Superoxide dismutase (SOD), catalase, glutathione peroxidase and peroxiredoxin are 
examples of antioxidant enzymes, which by catalysing the removal of ROS act as 
antioxidants. SOD catalyses the dismutation of O2•-, which generates O2 and H2O2. 
The human types of this enzyme include SOD1 (CuZnSOD present mostly in the 
cytosol but also in the intermembrane of the mitochondria), SOD2 (MnSOD present 
in the mitochondria) and SOD3 (extracellular glycosylated CuZnSOD)30. H2O2 that is 
formed during the dismutation of O2•-, can be eliminated by catalases, which catalyse 
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the dismutation of H2O2 to H2O and O2. Since H2O2 is an important molecule for cell 
signalling, the elimination of H2O2 is well regulated. Glutathione peroxidase is a 
family of enzymes reducing H2O2 to H2O (or lipid peroxides to alcohols) by 
selenocystein or cystein-dependent mechanisms leading to the oxidation of 
glutathione. The peroxiredoxin is an additional family of enzymes catalysing the 
reduction of H2O2. Glutathione is a thiol-containing tripeptide, functioning as a 
cellular redox buffer. Upon oxidation are two reduced glutathione (GSH) molecules 
linked via a disulfide bond, forming oxidised glutathione (GSSG). GSH can be 
regenerated by glutathione reductase. The ratio of GSH to GSSG is often used to 
express the redox state in a cell. 
 
Several proteins act as antioxidants by limiting the presence of free metal ions, to 
prevent Fenton reactions and the formation of the reactive OH•. Since both copper 
and iron are essential for many proteins, the management and transport of these ions 
are tightly controlled in order to avoid leakage and pro-oxidant effects. Transferrin, 
lactoferrin, ferritin, metallothionein, caeruloplasmin and albumin are examples of 
proteins that are sequestering and managing the transport of iron and copper.  
 
2.2.2 Dietary antioxidants 
Dietary micronutrients include vitamins, carotenoids, trace elements, flavonoids and 
other phytochemicals. Vitamins are small organic molecules required in human diet, 
due to a lack of capacity to synthesise them in sufficient amounts31. There are 13 
vitamins and they exert a broad range of functions including antioxidative properties. 
Vitamins A, C, and E are present in high levels in sea buckthorn berries and some of 
their physiological functions are presented below. 
 
Carotenoids, a group of red and yellow coloured pigments, can be found in a variety 
of fruits and vegetables. They, including β-carotene, are important for humans as 
precursors of vitamin A. All carotenoids derive from a skeleton of 40 carbon atoms. 
Vitamin A is a designation of a group of fat-soluble compounds that includes retinol, 
retinaldehyde, retinoic acid and retinyl esters. They all have vitamin A-activity and 
are essential for several biological processes in humans, including the immune 
system, vision, cell growth and cell differentiation1. Vitamin A is ingested through 
the diet as retinyl esters from animal sources, or as provitamin A from plant 
sources32. The Swedish dietary recommendations for vitamin A compounds are 700–
900 retinol equivalents (1 retinol equivalent = 1 µg retinol = 12 µg β-carotene) per 
day for healthy adults33. β-carotene is the most important provitamin A and is 
oxidatively cleaved in the intestine to achieve vitamin A-activity1. The carotenoids 
can act as antioxidants by quenching singlet oxygen, an important function in plant 
cells. In humans, the antioxidative effects of β-carotene are more uncertain and 
depend on the cellular environment. β-carotene can scavenge peroxyl radicals, 
forming an unstable β-carotene radical adduct that can further generate non-radical 
products34. However, if the oxidation products of β-carotene are not neutralised by 
other antioxidants, they can have pro-oxidative effects in the cell.  
 
Ascorbic acid, well-known as vitamin C, is a water-soluble nutrient that has two 
ionisable OH-groups, and at physiological pH, the mono-anion ascorbate is the 
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predominant form1. While most animals and plants are able to synthesise ascorbate 
from glucose, humans lack an enzyme needed for this synthesis and thus need to 
ingest vitamin C through the diet. Ascorbate is a cofactor for several enzymes, 
including the enzymes needed for the proper biosynthesis of collagen, carnitine, 
norepinephrine, tyrosine metabolism and amidation of peptide hormones35. Lack of 
vitamin C can cause scurvy, a deficiency disease that leads to defect collagen36. 
Vitamin C is also important for iron absorption in the intestines and contribute to the 
regulation of iron homeostasis37. Plasma levels of vitamin C are in the range of 50–60 
µM for healthy individuals, although the intracellular concentration can reach 1 mM 
in several cell types38. Ascorbate has a reducing ability and can act as a scavenger of 
ROS and RNS. The one-electron oxidation of ascorbate generates the ascorbyl 
radical, which can be further oxidised to dehydroascorbate. The antioxidant effect of 
ascorbate comes from replacing the damaging radicals by the less reactive ascorbyl 
radical. Ascorbate can also interact with the radical species from α-tocopherol and 
oxidised glutathione, regenerating the antioxidant molecules36. As vitamin C is a 
redox active molecule, it can also act as an oxidant. Pro-oxidative properties have 
been shown in vitro39,40, however, the potential harm of pro-oxidative effects in vivo 
has been questioned41. Recommended daily intake of vitamin C for healthy adults in 
Sweden is 75 mg33. 
 
Eight fat-soluble tocopherol and tocotrienol derivatives belong to the vitamin E 
compounds. Their chemical structure includes a chromanol ring with one to three 
methyl groups and a side chain that contains either three double bonds (tocotrienols) 
or a phytyl chain (tocopherols). Both types have four isomers, i.e. α, β, γ and δ. The 
α-tocopherol is considered to be the most bioavailable vitamin E in humans42, 
however, the importance of the other vitamin E compounds has been raised43. The 
vitamin E compounds are important for the cell membranes since they are able to 
scavenge peroxyl radicals, thereby inhibiting the free-radical chain reactions of lipid 
peroxidation. Tocopherols can also have pro-oxidative effects, by which the  
α-tocopherol radical may oxidise polyunsaturated fatty acids, which can lead to chain 
reactions of lipid peroxidation. Nevertheless, the rate constant of this reaction is 
much lower compared to the rate constant for the reaction between the peroxyl 
radical and the polyunsaturated fatty acids, and the importance of the α-tocopherol-
mediated peroxidation in vivo is under debate1. Moreover, vitamin A can prevent 
such oxidation by recycling the α-tocopherol radical44. Tocopherols can also protect 
cellular membranes against singlet oxygen by quenching44. The Swedish dietary 
recommendations for vitamin E compounds are 8–10 mg α-tocopherol equivalents  
(1 α-tocopherol equivalent = 1 RRR-α-tocopherol) per day for healthy adults33. 
 
2.2.3 Dietary supplementation 
There is epidemiological evidence that a diet rich in fruits and vegetables is inversely 
correlated with cancer, cardiovascular disease and mortality45-48. The positive health 
effects are often attributed to the vitamins and antioxidants, present in large amounts 
in fruits and vegetables. Therefore, much attention has been devoted to dietary 
supplements containing vitamins and antioxidants. However, human intervention 
studies have often failed to show beneficial health effects of vitamin supplements. 
Meta-analyses have even showed increased mortality associated with the intake of   
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β-carotene and potentially vitamin E and vitamin A3. The results highlight the 
complexity in the topic of antioxidant supplementation, suggesting that there are 
other important functions of the vitamins, and/or other components of fruits and 
vegetables, that play significant roles in disease prevention. The supplements studied 
have often contained single or a few vitamins at high concentrations, which can 
potentially disturb the balance in the redox state of cells and organisms. However, the 
studies also indicate that there may be certain groups that would benefit more from 
dietary supplementation, which potentially include poorly nourished groups, with low 
baseline nutritional status. For instance, in the Chinese Linxian study, with 
participants of poor nutritional health, the mortality decreased after supplementation 
with α-tocopherol, β-carotene and selenium49. Moreover, in the French SU.VI.MAX 
study it was found that supplementation with multivitamins and minerals lowered the 
incidence of cancer and mortality in men50. The beneficial effect was not seen among 
women and it was suggested to be due to the lower baseline levels of vitamin C and 
β-carotene in men compared to women. It must also be noted that some groups, such 
as smokers, are more susceptible for increased health risks of β-carotene 
supplementation, as observed in the CARET and the ATBC studies51,52. 
 
 
2.3 SEA BUCKTHORN 
Extracts of fruits, vegetables and berries are applied as dietary supplements in an 
approach to mimic the natural content of the original specie. The sea buckthorn berry, 
seen in Figure 5, has recently raised more interest in the Western world, both as a 
part of the diet or dietary supplement, as well as in skincare products. Sea buckthorn 
has traditionally been used as a medicinal plant for several hundred years in China, 
Turkey and Russia. There are seven subspecies of sea buckthorn with different 
geographical origin; Hippophae rhamnoides L. is the most frequently grown species 
in Europe. The berry contains high levels of unsaturated fatty acids, vitamin C, 
vitamin E, carotenoids and phytochemicals including flavonoids and other phenolic 
compounds. The nutrient content varies among the different species and the 
geographic growth place as well as also among the different parts of the berry53. 
 
 
 
 
Figure 5. Sea buckthorn berries in the Swedish archipelago, photo by Eva Larsson. 
 
  11 
The sea buckthorn berry has been attributed with antioxidative, anti-tumour, anti-
proliferation and anti-inflammatory properties as well as immune response regulatory 
effects7,54-58. Recently, Widén et al.59 demonstrated an antibacterial activity of sea 
buckthorn juice and suggested that it may reduce the risks for tooth decay and 
gingivitis. While most available studies are in vitro or in vivo animal studies using 
different extracts of the berry, only a few human studies on whole sea buckthorn 
berries or extracts have been published. Reported effects in humans include inhibition 
of induced platelet aggregation60, reduction of serum levels of C-reactive protein 
(CRP)8, metabolic effects61 and an attenuated increase of tear film osmolarity in 
people suffering from dry eyes symptoms9. 
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3 CHRONIC KIDNEY DISEASE  
 
3.1 RENAL FAILURE 
In CKD, the functional units of the kidneys, the nephrons, are progressively lost, 
which causes a decrease in renal function. This will lead to an augment of uremic 
symptoms including increased levels of urea and creatinine in the blood, anaemia and 
disturbances in the electrolyte and water balance. End-stage renal disease is managed 
by a protein-reduced diet, medication for hypertension and anaemia, correction of 
electrolytes, as well as renal replacement therapy including dialysis treatment or 
kidney transplantation. Dialysis treatment, performed to replace an impaired kidney 
function, is an artificial purification of the blood where waste products are removed 
and the balance between salts and fluids can be regulated. In haemodialysis, the 
blood is pumped out of the patient’s body and filtered using a dialyzer before it 
returns to the patient. The dialyzer is designed with a semi-permeable membrane 
allowing passage of substances and fluids between the blood and the dialysate. In 
peritoneal dialysis, the exchange of substances and fluids is performed using the 
patient’s peritoneal membrane inside the abdomen as a filter62. 
 
 
3.2 OXIDATIVE STRESS, INFLAMMATION AND ORAL HEALTH IN 
KIDNEY DISEASE 
Kidney failure is associated with high levels of oxidative stress, inflammation and 
malnutrition. These factors are closely related and contribute to the higher risk for 
cardiovascular disease, atherosclerosis and cancer in CKD patients63-66. Elevated 
levels of oxidative stress are frequently reported in CKD patients4,67-69. Beyond the 
generation of ROS during normal cellular metabolism, potential sources of oxidative 
stress in CKD patients also include elevated systemic inflammation, incidence of 
diabetes, the dialysis treatment, reduced dietary intake of antioxidants and the 
accumulation of uremic toxins. Raised levels of inflammation markers, such as 
specific cytokines and acute-phase reactants, are often observed in CKD 
patients4,67,68. 
 
The dialysis treatment itself can also be a source of oxidative stress and 
inflammation. The contact between the blood and the dialysis membrane can trigger 
inflammatory reactions and alterations in the constitution of blood cells during 
dialysis. The activation of the complement system depends on the biocompatibility of 
the dialysis membrane. For instance, Memoli et al.70 showed that peripheral blood 
mononuclear cells (PBMC) collected after cuprophane membrane-haemodialysis 
produced higher levels of interleukin (IL)-12 compared to polymethylmethacrylate 
membrane-haemodialysis, in both healthy controls and CKD patients. ROS can also 
be generated in the process of neutrophil activation during which the NADPH 
oxidase complex throughout the respiratory burst produces O2-. In addition, dialysate 
impurities such as endotoxins and bacterial cell wall fragments, can stimulate the 
activation of monocytes and the production of cytokines including IL-1 and TNFs71.  
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The prevalence of anaemia, characterised by a decreased number of red blood cells, 
is high in CKD patients. Anaemia can be a consequence of several factors including a 
reduced production of erythropoietin (a hormone important for production of red 
blood cells), blood loss, lack of available folate and vitamin B12, and iron deficiency. 
Impaired erythropoiesis is improved by erythropoiesis-stimulating-agents and 
supplementation with oral or intravenous iron. However, appropriate dosing of iron is 
complex, as an iron overload can contribute to the increased risk for cardiovascular 
disease in CKD patients72. Iron supplementation is a potential source of oxidative 
stress since free iron, not bound to iron-binding proteins such as transferrin, can 
participate in Fenton reactions generating hydroxyl radicals. Lipid peroxidation has 
been shown to increase shortly after intravenous iron infusion73,74. However, the 
significance of these pro-oxidative effects is uncertain and the benefits of iron 
supplementation upon iron repletion and anaemia are central75. Intravenous iron 
supplementation in appropriate doses and preparation is widely used and 
recommended72,76. 
  
Malnutrition and protein-energy wasting are considered as additional risk factors for 
the high mortality observed in CKD patients77,78. Dietary restrictions, such as reduced 
intake of proteins, potassium, sodium, phosphorus, calcium and excess fluid, may be 
required to diminish the complications of kidney failure and dialysis treatment. 
Alteration in the diet, in some cases with reduced intake of fruits and vegetables in 
order to evade hyperkalaemia and decrease levels of phosphorus and calcium, is a 
potential cause of antioxidant deficiency79. Water-soluble vitamins such as vitamin B 
and vitamin C are also lost during the dialysis treatment. 
 
The oral health status is known to affect the general health of humans; inflammation 
and complaints in the oral cavity increase the systemic inflammation and contribute 
to atherosclerosis and cardiovascular disease development80. Poor oral health is 
common among CKD patients81. Several studies report impaired oral health status 
including periodontitis (tooth loss), xerostomia (mouth dryness), mucosal lesions, 
gingival enlargement, and changes in the saliva5,82-84. The impairments can be caused 
by medications, reduced oral care by the patients, increased levels of carbohydrates in 
the diet or by dysfunction of the immune defence caused by the uraemia and dialysis 
treatment85. Oxidative stress and damage to the salivary gland tissue have been 
suggested as underlying factors to oral complaints86. Appropriate function of the 
salivary glands is necessary for a good saliva production and oral health. The 
production of the saliva is managed by three pairs of major salivary glands and 
hundreds of minor salivary glands throughout the mouth. The inner lip area, as seen 
in Figure 6, is one of the locations with abundant number of minor salivary glands. 
The saliva is essential for maintaining a good oral health by protecting the oral tissue 
from infections and breakdown. Measurements of saliva constituent as well as saliva 
production, can provide information regarding salivary gland function and oral health 
status.  
  14 
 
 
Figure 6. Several hundreds minor salivary glands are present throughout the oral cavity (located in 
lips, cheeks, hard and soft palate and the tongue), photo courtesy Amela Trbakovic, DDS. 
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4 TOXICITY AND BIOCOMPATIBILITY OF 
NANOPARTICLES 
 
4.1 NANOTECHNOLOGY 
Nanotechnology can be described as the technology in which objects that are in the 
size-range of nanometres are produced, engineered or utilised. The prefix nano refers 
to a factor of 10-9, which means that 1 nanometre (nm) is equal to a billionth of a 
meter. Nanotechnology has developed rapidly during recent years and applications of 
nanomaterials can be found within several sectors in the society. The key feature of 
nanomaterials is their small size. The small size can yield unique physicochemical 
properties, different from larger-sized particles and bulk material of the same 
chemical composition. One key factor behind the difference is the large percentage of 
atoms localised on the surface of the particles, that is, the smaller-sized particles have 
a larger surface area-to-mass ratio87. In addition, the surface atoms have lower 
coordination number and are less stable than the bulk atoms. This is especially 
relevant for nanoparticles less than 30 nm in size, where it can influence the surface 
reactivity and melting point88. Another key factor is the impact of quantum effects, 
which can alter optical and magnetic properties, conductivity and catalytic activity of 
nanomaterials89. It should be noted that the impact of these factors varies with 
particle size within the nanoscale, and also depends on the chemical composition and 
crystalline structure of the particle. The possibility to tune these properties makes 
nanomaterials highly attractive for several applications.  
 
Even though the anthropogenic sources of nanoparticles have increased in recent 
years, the presence of nano-sized materials is not new, as humans have been exposed 
to nanoparticles throughout the evolution. Examples of sources of naturally occurring 
nanoparticles are volcanic ash, sea spray and smoke from forest fires. The 
anthropogenic sources of nanoparticles include, in addition to the intentional 
production, unintentional formation through combustion, tire wear, in the subway and 
during welding. Due to the rapid development of nanotechnology and the 
unintentional formation during processes in the industrial society, the potential for 
human exposure to nanoparticles has increased. As seen in Figure 7, nanoparticles 
are in the same size-range as cellular structures, which can potentially lead to 
alterations in the interactions with cells and cellular molecules. As adverse health 
effects of nanoparticles have been observed, concerns regarding the safety of 
nanoparticles have been raised90,91. 
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Figure 7.  Nano- and microsized materials in a logarithmic length scale for a comparison with the size 
of biological molecules and cells, reprinted from Buzuea et al.89 with the permission from AIP 
Publishing LLC. Copyright 2007, American Vacuum Society.  
 
4.2 DEFINITIONS OF NANOMATERIALS 
There are no harmonised international definitions of nanomaterials or nanoparticles. 
Generally, a nanomaterial is defined as a material with at least one dimension in the 
size-range between 1–100 nm, while a nanoparticle is often defined as an object with 
all dimensions between 1–100 nm. These general definitions are used within this 
thesis. According to the European Commission, a more specific definition of a 
nanomaterial is: 
 
 “‘Nanomaterial’ means a natural, incidental or manufactured material containing 
particles, in an unbound state or as an aggregate or as an agglomerate and where, 
for 50 % or more of the particles in the number size distribution, one or more 
external dimensions is in the size range 1 nm–100 nm.”92 
 
By this definition, particle, agglomerate and aggregate are further defined as: 
 
“(a) ‘particle’ means a minute piece of matter with defined physical boundaries; 
(b) ‘agglomerate’ means a collection of weakly bound particles or aggregates 
where the resulting external surface area is similar to the sum of the surface areas 
of the individual components;  
(c) ‘aggregate’ means a particle comprising of strongly bound or fused particles.”92 
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The definition above includes both naturally occurring and anthropogenic 
nanomaterials. The term engineered nanomaterial is often used to describe an 
intentionally produced nanomaterial with specific properties.  
 
4.3 ENGINEERED NANOMATERIALS AND THEIR APPLICATIONS 
Nanotechnology enables engineering at the nanoscale to produce materials with 
attractive properties. Nanomaterials include materials with different chemical 
compositions and shapes, such as nanofibers, nanorods, nanospheres, nanotubes and 
nanosheets. Commonly used materials include carbon, silica, different metals and 
metal oxides, ceramics and polymers. Due to the diversity in both shape and 
composition within nanomaterials, and the possibility to tune these properties for the 
desired purpose, the application areas are of wide variety.  
 
The global market for nanotechnology products was approximately 254 billion US 
dollars in 2009 and it is estimated to reach 3000 billion US dollars in 202093. In an 
inventory of nanotechnology-based consumer products presented by The Project on 
Emerging Nanotechnologies, were 1628 nanoproducts listed as of October 201394. 
The most common product category was found to be products within health and 
fitness, and the major materials reported were silver (Ag), titanium and carbon. Silver 
nanoparticles can be used for antibacterial and anti-odour functions in sports clothing 
or for wound dressing in biomedical applications94,95. Titanium dioxide (TiO2) 
nanoparticles have versatile properties and can be found in cosmetic products, sun 
screens, food and paints96. Nano-sized carbon black is one of the most produced 
nanomaterials and it is used in the production of rubber products and also as a 
pigment. Furthermore, zinc oxide (ZnO) nanoparticles are highly attractive for 
various applications, partly due to their optical properties. Copper (Cu) and copper 
oxide (CuO) nanoparticles are used for antimicrobial purposes in surface coatings, 
woods, textiles and paints97. Furthermore, nanotechnology can be applied within the 
environmental technology area for water purification, to decrease pollution and 
capture carbon dioxide98,99. 
 
4.3.1 Nanomedicine 
Nanomedicine is a promising and fast developing field that covers several biomedical 
applications using engineered nanomaterials. Nanoparticles can be designed for 
efficient drug and gene delivery, diagnosis, in vivo imaging, or combinations of these 
functions. Moreover, applications of nanomaterials include biomedical implants, 
biosensors and tissue regeneration. 
 
Liposomes, polymers and metal nanoparticles are commonly applied entities in 
nanomedicine and several nanomedicines are evaluated in clinical trials, whereas 
some have already reached the market100. Combined therapeutic and diagnostic 
properties, so called theranostics, is emerging as a promising approach to develop 
personalised medicine with the possibility to monitor drug distribution and treatment 
progress101. This is appealing not at least in cancer treatment. Nanosized drug-
delivery systems can be used to improve the solubility and the pharmacokinetics of 
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conventional drugs, with the aim to increase the therapeutic index. They offer 
possibilities to improve and control the biodistribution of the drug, by passive and 
active targeting with ligands, as well as control of drug release upon internal or 
external stimuli. The passive targeting of nanoparticles to tumour tissue occurs via 
the enhanced permeability and retention (EPR) effect, which is caused by the 
enlarged fenestrations between endothelial cells, as well as impaired lymphatic 
drainage of tumour tissue, leading to a longer retention of nanoparticles102.  
 
Gene therapy is a therapeutic approach based on the delivery of nucleic acids, either 
DNA or RNA, to regulate gene function. Successful gene therapy is dependent on 
efficient and non-toxic delivery vectors, as naked/unmodified DNA or RNA will be 
degraded by nucleases or rapidly excreted. Owing to the high loading capacity and 
the potential ability to control their biodistribution, nanoparticles are of interest as 
vectors for the delivery of genes. Gold nanoparticles103, carbon nanotubes104, 
dendrimers105 and silica nanoparticles106 are examples of nanomaterials that have 
been explored for application as gene delivery systems. Even though gene therapy is 
a promising therapeutic approach for several diseases, inefficient gene delivery and 
toxic vectors are still challenges to overcome. Barriers that need to be considered are; 
the stability of the DNA/RNA vector complex, undesired enzymatic degradation, 
rapid renal clearance, unspecific toxicity, cellular internalisation, endosomal 
entrapment and lysosomal degradation, as well as the nuclear import in the case of 
DNA delivery107.  
 
4.3.2 Silica nanoparticles 
Mesoporous (materials with pore diameters between 2 and 50 nm) silica (silicon 
dioxide) nanoparticles have gained a lot of attention for usage within nanomedicine, 
as they are presenting several interesting properties including tuneable diameter and 
pore size, high surface area and good biocompatibility108. Silica has large amounts of 
silanol (Si-OH) groups on the surface, which by chemical modifications can be 
functionalised with different organic groups with desired function. For example, 
targeting ligands including peptides, antibodies or small molecules such as folic acid 
can be conjugated to increase the active targeting to tumour tissues. Moreover, 
surface modification with polyethylene glycol (PEG) chains can be used to reduce 
non-specific binding of proteins, and thereby avoid clearance by the 
reticuloendothelial system, resulting in a longer blood circulation time109. The 
structure of the mesoporous silica nanoparticle allows for loading of molecules/drugs 
within the pores, and by applying so called gatekeepers, the release of the cargo can 
be controlled. For instance, pH or redox state sensing entities can be applied to 
control the release upon stimuli110,111. 
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4.4 NANOTOXICOLOGY 
Along with the increased spread of nanomaterials in the society, questions regarding 
the safety of these materials have been raised90,91. The properties of nanoparticles that 
make them attractive for applications can also alter the interactions with biological 
systems and bring on adverse health effects. Their small size can lead to alterations in 
exposure, translocation, cellular uptake and intracellular fate. Nanoparticles may have 
the potential to travel inside organisms and penetrate tissues and cells in a greater 
extent compared to larger particles and bulk form. The term nanotoxicology has been 
proposed to describe the branch of toxicology that comprises research on toxic effects 
of nanomaterials112. One important aspect of nanotoxicology is that materials in the 
nanoscale may be more toxic compared to their equivalent bulk form. However, the 
nanosize per se do not necessarily imply a hazard, and not every nanomaterial is 
toxic. It has been argued that there are no nano-specific mechanisms that drive the 
toxicity of certain nanoparticles113. However, there are certain matters that need to be 
considered in nanotoxicology. Generally, in toxicology the dose makes the poison. 
Dose metric is of consideration in nanotoxicology and it has been suggested that 
particle surface area is an appropriate dose metric to be used in nanotoxicology 
studies12. In addition to dose, particle characteristics including the size, shape and 
surface properties are important factors influencing the toxicity. Much knowledge 
can be obtained from previous studies on particle toxicology, particle kinetics, 
epidemiological studies on airborne particles and also from the field of metal toxicity 
in the case of metal nanomaterials. 
 
Understanding the interactions of nanomaterials with biological systems is crucial for 
risk assessments and a safe development of nanotechnology products, not least for 
safe and effective nanomedicine. This includes understanding of the exposure routes, 
possible translocation to other organs, cellular uptake and mechanisms of toxicity. 
 
4.4.1 Exposure to nanoparticles 
The public can be exposed to nanoparticles that are either formed naturally, during 
combustion or during other unintentional formation processes. In addition, exposure 
to nanoparticles can occur via usage of consumer products containing nanoparticles 
or via the release of nanoparticles from these products. Furthermore, occupational 
exposure to nanoparticles is an important health risk for workers within mining, 
welding or other activities where nanoparticles are formed intentionally or 
unintentionally. Routes of exposure depend on the origin, production or application 
of the nanoparticle or nanoparticle product. Exposure can occur via inhalation, 
ingestion and dermal exposure both for the general public and in occupational 
settings, while injection and implants are other possible exposure routes when 
applying biomedical products. 
 
Lung exposure 
Exposure to ambient particles is known to increase the risk for cardiovascular disease 
and increase mortality and morbidity114. Nanosized particles are considered to 
contribute more to the negative health effects compared to the larger particles.  
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Upon inhalation, particles deposit in the lung depending on their size, composition 
and breathing conditions such as breathing strength. The mechanisms that determine 
the site of deposition include sedimentation (gravitational forces), inertial impaction, 
interception (contact with the airway surface), electrostatic forces and diffusion. For 
nanoparticles, diffusion is the most important mechanism12. In a mathematical model 
developed by the International Commission on Radiological Protection, are inhaled 
particles, depending on their size, predicted to deposit in different mass proportions 
in the different regions of the respiratory system12,115. According to this model, 
nanoparticles can deposit in all three regions (the upper respiratory tract, the 
tracheobronchial region and the alveolar region) of the human respiratory system, as 
shown in Figure 8. Single particles with a size around 1 nm, and larger particles 
around 10 µm, deposit predominantly in the upper part of the respiratory system. 
Particles with a size of 20 nm deposit mostly in the alveolar region (approx. 50%) as 
well as in the upper region and the tracheobronchial region (approx. 15% in each of 
them). Particles with a size of 5 nm deposit in equal proportions (approx. 30%) in 
each of the three regions. 
 
 
 
 
Figure 8. Illustration of size-dependent deposition of particles in the lung, predicted by a model 
developed by the International Commission on Radiological Protection 1994115. The figure is adapted 
from Oberdörster et al.12, with the permission from Environmental Health Perspectives. 
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The clearance of the inhaled particles depends on the site of the deposition and also 
the particle characteristics. Certain particles can be cleared via chemical processes 
and dissolution, which are processes that can be rather independent on the region of 
deposition. Mucociliar clearance of deposited particles occur in the conductive 
airway where the particles become trapped in the mucus and are transported via 
ciliary movement up to the pharynx to be swallowed or coughed out116. The main 
clearance mechanism in the alveolar region is via phagocytosis by alveolar 
macrophages116. Upon phagocytosis of the particles, macrophages move to the 
ciliated regions and are cleared via mucociliar clearance. The retention time is longer 
for particles that deposit in the lower region of the respiratory tract117. While the 
phagocytic processes occur in a couple of hours, the gradual movement towards 
mucociliar clearance can take up to 700 days in humans12. It has also been shown that 
the phagocytic efficiency is size-dependent with small nanoparticles having the 
potential to escape the macrophages118. The length of nanofibers can also affect the 
phagocytic clearance. An increase of length of the nanofiber can impair the clearance, 
following the paradigm of fibre toxicity with similarities to asbestos119. Failure in 
phagocytic clearance and a longer retention time could potentially lead to increased 
inflammation, cellular interactions and uptake by epithelial cells and further 
translocation of the nanoparticle to the circulatory system and other organs. The 
extent of translocation is however debated and conflicting findings are presented in 
the literature117,120-122. Wiebert et al.123 showed that less than 1% of inhaled carbon 
nanoparticles were translocated from the lung in healthy human subjects.  
 
Oral exposure 
Nanoparticles in food, toothpaste and cosmetics, as well as inhaled and mucociliary-
cleared nanoparticles, can reach the gastro-intestinal tract. Thus, the complex gastro-
intestinal tract, acting as both a site for exchange of macromolecules and a barrier, is 
a potential entry route for nanoparticles. Translocation across the gastro-intestinal 
mucosa can occur via endocytosis by epithelial cells, transcytosis by M-cells in the 
Peyer’s patches, via persorption through gaps in the epithelium or potentially by 
paracellular uptake124. The rate of persorption through the mucous layer has been 
shown to be dependent on the size, with smaller nanoparticles crossing the layer 
faster125. After reaching the sub-mucosal tissue, nanoparticles can enter the lymphatic 
system and be further translocated to the blood and other organs126.  
 
Dermal exposure 
Dermal exposure to nanoparticles can occur unintentionally via environmental or 
occupational exposure, or intentionally by usage of consumer products such as 
sunscreens and cosmetics containing nanoparticles. The skin consists of several 
layers that form a barrier to prevent the entry of toxic substances and pathogens into 
the body. Generally, the skin is considered to be a good barrier preventing 
nanoparticle entrance with several studies showing that nanoparticles do not penetrate 
intact skin89,127,128. However, a study by Murugan et al.129 showed that TiO2 
nanoparticles can lodge in the hair follicles, but further penetration was not shown. 
The potential penetration of nanoparticles through damaged or flexed skin is 
unclear129. 
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4.4.2 Cellular uptake and mechanisms of toxicity 
Interactions of nanomaterials with living cells may cause toxic effects. Undesired 
effects include cytotoxicity, morphological and structural changes and genotoxicity. 
Although the exact toxic mechanisms are not fully understood, key events in the 
toxicity of nanomaterials are considered to be oxidative stress, DNA damage and 
inflammation130.  
 
Cellular uptake 
The passage of molecules and particles through the cell membrane can occur via a 
passive or active transport. Most particles and larger macromolecules enter the cells 
by endocytosis. Phagocytic cells are able to take up larger particles via phagocytosis, 
a specific type of endocytosis, whereas non-phagocytic cells utilise different 
pathways of pinocytosis to mediate cellular uptake. Upon cellular uptake, 
nanoparticles can end up in lysosomes, be transported out of the cell, or reach 
organelles, such as the mitochondria or nuclei. The cellular uptake of particles 
depends on the physicochemical properties including the particle size, shape, surface 
properties and modifications such as possible target ligands, as well as the extent of 
particle aggregation131. In Figure 9, potential mechanisms of cellular uptake of 
nanomaterials are shown, illustrated by Zhao et al.132. 
 
 
 
 
Figure 9. Illustration of potential cellular uptake and intracellular fate of nanomaterials. Reprinted 
from Zhao et al.132 with permission from John Wiley and Sons. 
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Oxidative stress 
Reactive oxygen species can be generated directly on the nanoparticle surface, as a 
consequence of particle dissolution, due to direct damage of cellular compartments 
(e.g. the mitochondria), or as secondary formation due to activation of the immune 
system or impaired protein function. As described in section 2, cells can make 
adaptions to increased levels of oxidative stress. The three-tier model of cellular 
responses to oxidative stress induced by ambient particulate pollutants, as seen in 
Figure 10, can in similarity, be applied as a oxidative stress paradigm for the toxicity 
of nanoparticles133. According to this model, at low levels of oxidative stress (Tier 1), 
the nuclear factor erythroid 2-related factor 2 (Nrf-2) can induce the expression of 
antioxidative and detoxifying phase II enzymes such as haem oxygenase 1 (HO-1), 
glutathione S-transferase (GST) and catalase, to maintain the redox balance. Failure 
in the antioxidative response, and/or increased ROS levels, may result in 
inflammatory effects (Tier 2). The inflammatory response is regulated by redox 
sensitive mitogen-activated protein kinase (MAPK) and NF-κB, which can increase 
the production of cytokines and chemokines. Further increase of oxidative stress may 
lead to cytotoxic effects (Tier 3) with the release of pro-apoptotic factors and cell 
death133. 
 
 
 
Figure 10. The toxicity of nanoparticles can in similarity to the toxicity of ambient particulate 
pollutants, be described by an oxidative stress paradigm with three tiers of cellular response depending 
on the level of oxidative stress. Illustration from Li et al.133, reproduced with permission from Elsevier. 
 
Nanoparticles composed of metal and metal oxides can exert toxicity by extra- or 
intracellular dissolution resulting in a release of potentially toxic ions. The cell 
membrane normally acts as a barrier preventing the entrance of ions by regulating 
the uptake through metal sensing and transport proteins134. However, a Trojan 
horse-type of mechanism is commonly used to describe an endocytic uptake of 
nanoparticles whereupon reaching the inside of the cell, in the acidic pH (pH in the 
lysosomes ≈ 4.5), they are dissolved and release toxic ions135,136. The release of 
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transition metal ions, such as Cu, Fe, Cr, Mn, can initiate redox reactions and 
generation of hydroxyl radicals through Fenton reactions. Other toxic mechanisms 
of metal ions include non-specific binding to protein ligands and competition with 
other essential metals resulting in dysfunctional proteins. 
 
In contrast to pro-oxidative effects of nanoparticles, cerium oxide (CeO2) 
nanoparticles have been shown to have antioxidative and cytoprotective effects. It 
was shown in a vein endothelial cell line that nanoceria exerted protective effects on 
H2O2-induced mitochondrial damage and thereby prevented oxidative damage137. 
Korsvik et al.138 demonstrated that the antioxidative effect of CeO2 mimics the 
catalytic activity of SOD, with the nanoparticles exhibiting a higher catalytic rate 
constant, probably due to the large particle surface area with several catalytic sites.  
 
Genotoxicity 
Nanoparticle exposure can induce DNA damage either by indirect or direct 
interactions with the DNA. Indirect DNA damage can be induced when nanoparticles 
affect proteins important for regulation of the genes or the cell cycle, or by inducing 
ROS formation and increased oxidative stress levels139. Direct interactions with the 
DNA can occur upon nuclear entrance via the nuclear pores, however, this is most 
likely limited owing to the structure of the nuclear pore complex. Nonetheless, in 
vitro studies have showed that small nanoparticles (<10 nm) can access the nuclei, 
e.g. gold nanoparticles (2 and 6 nm)140 and SiC nanocrystals (4 nm)141. Larger 
nanoparticles have also been detected in the nucleus. For instance, silica 
nanoparticles with a diameter of 70 nm were shown to enter the nucleus in HaCaT 
cells (human keratinocytes)142 while silicon carbide nanoparticles (10–60 nm) were 
detected in the nucleus in A549 cells (human lung cells)139. Larger nanoparticles may 
have direct interactions with the DNA during the mitotic phase, during which the 
nuclear membrane breaks down. 
 
Indirect DNA damage can occur due to increased levels of ROS, as described in 
section 2.1.1. Since both nanoparticles and ROS can potentially inactivate proteins, 
indirect DNA damage can also emerge if proteins involved in DNA repair, 
replication or transcription are damaged139. Moreover, some nanoparticles including 
silica, have been shown to induce epigenetic changes143. 
 
Inflammation 
Activation of the inflammatory system is a normal cellular response to invading 
pathogens, particles, cell injuries, chemicals or other potential harmful substances. 
The innate immune system provides a rapid inflammatory response, potentially 
within minutes upon triggering. Activation of phagocytic cells upon nanoparticle 
engulfment can initiate cascades of pro-inflammatory molecules (cytokines and 
chemokines) to recruit and activate other immune cells. In addition, release of ROS 
through activation of NADPH-oxidase and oxidative burst can occur.  
 
Nanoparticles can be designed to target or to avoid the activation of the immune 
system, depending on the application and the desired effect. Non-functionalised 
carbon nanotubes were shown not to trigger engulfment or oxidative burst in 
macrophages, whereas surface modifications with phosphatidylserine (PS) increased 
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the uptake by macrophages144,145. Certain nanoparticles can also act in an 
immunosuppressive way and decrease the ability of the body to recognise 
pathogens146. For instance, Lundborg et al.147 showed that ingestion of ultrafine 
carbonaceous particles by macrophages impaired their ability to phagocyte. Such 
impairment could lead to increased susceptibility to infections. 
 
4.4.3 Physicochemical properties influence the biological interactions 
The biological responses upon exposure to nanoparticles can be different for each 
type of nanoparticle as they depend on the physicochemical properties of the 
nanoparticle. Particle characteristics influencing the cellular interactions and toxicity 
include size, chemical composition, shape, surface area, surface charge, crystallinity, 
solubility, agglomeration state and possible surface coating. The surface properties of 
the particle will affect the binding of proteins and other biomolecules when in contact 
with biological fluids. This protein corona changes the hydrodynamic size and the 
surface charge, and it will dictate the biological fate and the toxicity of the particle148. 
Therefore, thorough investigation of physicochemical properties is essential when 
evaluating toxicity and potential biomedical use of nanomaterials. 
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5 RESEARCH AIMS 
The general aim of this thesis was to study oxidative stress, DNA damage and toxic 
mechanisms induced by either kidney disease or nanoparticles. Studies on CKD and 
dietary supplementation in vivo, as well as nanoparticle exposure in vitro are 
included.  
 
The specific aims of the studies included in this thesis are as follows: 
 
– Assess the levels of oxidative stress and DNA damage in minor salivary glands, as 
well as investigate the correlation with saliva production, inflammation and uremic 
markers in patients with CKD. (Study I) 
 
– Investigate the effects of a dietary supplement containing sea buckthorn extract on 
oxidative stress and DNA damage in minor salivary glands, as well as saliva 
production, inflammation and uremic markers in patients with CKD. (Study II) 
 
– Compare the cytotoxicity of a range of nano- and microsized particles and screen 
for particularly toxic particles in vitro.  
 
– Investigate differences in the cytotoxicity of selected nanoparticles among different 
cell types.  
 
– Investigate the toxicity of Cu-based nanoparticles (Cu and CuO nanoparticles) and 
study toxic mechanisms including oxidative stress, DNA damage, mitochondrial 
damage and cell death in vitro. (Study III) 
 
– Study the biocompatibility of amine-modified silica nanoparticles and examine 
their potential use as vectors for delivery of plasmid DNA in vitro. (Study IV) 
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6 STUDY APPROACH  
The first part of this thesis is based on an observational study investigating the levels 
of oxidative stress, DNA damage and inflammation in CKD patients, and an 
intervention study of a dietary supplement containing a sea buckthorn extract in the 
same patient group. The second part of this thesis is based on in vitro studies on 
toxicity, biocompatibility and application of nanoparticles.  
 
 
6.1 STUDY I AND II: DNA DAMAGE AND OXIDATIVE STRESS IN 
CHRONIC KIDNEY DISEASE PATIENTS 
The main aim of Study I, the observational study, was to assess the levels of DNA 
damage and oxidative DNA damage (as a biomarker for oxidative stress) in salivary 
glands, as well as to investigate the correlation with saliva production, inflammation 
and uremic markers. It has previously been shown that CKD patients have higher 
levels of DNA damage and oxidative stress in PBMC, and that CKD patients often 
suffer from impaired oral health. Thus, it was hypothesised that elevated levels of 
DNA damage and oxidative DNA damage can also be found in the salivary glands of 
CKD patients, with potential correlation with hyposalivation. No previous studies on 
DNA damage in the salivary glands in this patient group have been found in the 
literature. The patient group of 79 CKD patients, of whom 69 were dialysis patients 
(66 haemodialysis patients and 3 peritoneal dialysis patients) and 10 were predialysis 
patients (CKD patients not yet on dialysis), was recruited from the Karolinska 
University Hospital and other dialysis units in Stockholm. Control patients were 
recruited from the public dental service clinic in Solna and were age- and sex-
matched to the CKD patients. Biopsies of the minor salivary glands were collected by 
incision and frozen prior to DNA damage analysis with the comet assay. Blood and 
saliva samples were collected as well.  
 
In Study II, the intervention study, the main aim was to study the effects of a dietary 
supplement containing an oil extract of sea buckthorn on oxidative stress and DNA 
damage in salivary glands in haemodialysis patients. In addition, effects on saliva 
production, inflammation and uremic markers were also investigated. Since previous 
studies on sea buckthorn have shown antioxidative effects in vitro55,56 and beneficial 
effects on mucous membranes in vivo9, it was hypothesised that supplementation 
with sea buckthorn extract would have beneficial effects on DNA damage and 
oxidative DNA damage in the salivary glands as well as improve oral health in terms 
of increase of saliva production. The study was a randomised, double-blinded 
crossover study with 2 × 8 weeks treatment periods. The study design is shown in 
Figure 11. A four-week wash-out period was applied in between the treatment 
periods to avoid carry-over effects. The study subjects were 63 haemodialysis 
patients recruited from the Karolinska University Hospital in Stockholm. The patients 
were randomly assigned in two patient groups with different treatment sequences. 
The first group received sea buckthorn capsules during the first study period and 
placebo capsules during the second period, while the other group received placebo 
capsules in the first period and sea buckthorn capsules in the second period. The 
  28 
intake was instructed to four capsules per day. The content of the sea buckthorn 
capsules and the daily dose are shown in Table 2. The daily doses of vitamin A and 
vitamin E were both slightly less than half of the recommended daily intake in 
Sweden, see section 2.2.2. Appointments to collect salivary gland biopsies, blood and 
saliva samples were conducted before and after each treatment period, i.e. in total 
four appointments per patient. The comet assay was used to assess the levels of DNA 
damage and oxidative DNA damage in the salivary glands. 
 
 
 
 
Figure 11. A scheme of the study design in the intervention study (Study II), wherein the effect of 
supplementation with the sea buckthorn oil (SBO) extract in haemodialysis patients was evaluated. 
 
 
 
 
 
1 SBO capsule (500 mg) Daily dose (4 capsules, 2 g)
Oleic acid (C18:1 n-9) 124 mg (24.8%) 496 mg
Palmitoleic acid (C16:1 n-7) 97  mg (19.5%) 388 mg
Linoleic acid (C18:2 n-6) 92 mg (18.4%) 368 mg
!-linolenic acid (C18:3 n-3) 63 mg (12.6%) 252 mg
Vitamin E 931 µg 3.7 mg
Vitamin A 88 µg 352 µg 
Table 2. Capsule content and daily dose of the sea buckthorn supplement. 
Haemodialysis patients 
(n=72) 
SBO 
(n=33) 
Placebo 
(n=30) 
Placebo 
(n=21) 
SBO 
(n=24) 
Dropouts (n=12) 
Deaths (n=2) 
Non-compliance (n=3) 
Acute illness (n=7)  
Dropouts (n=6) 
Acute illness (n=6)  
Excluded patients (n=9) 
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6.2 STUDY III AND IV: TOXICITY AND BIOCOMPATIBILITY OF 
NANOPARTICLES 
The aims of the second part of this thesis were to identify particularly toxic 
nanoparticles as well as biocompatible nanoparticles, by screening a range of nano- 
and microparticles, and to further examine the toxic mechanisms. Initially, a range of 
37 different particles was screened for their cytotoxicity in the human lung cell line 
A549 using the trypan blue exclusion assay. Subsequently, a selection of the particles 
was further compared in five additional human cell types to explore any cell type-
specific cytotoxicity. The studied cell types were A549 (lung carcinoma cell line), 
HL60 (acute myeloid leukaemia M2 cell line), Jurkat cells (T lymphocytic cell line), 
K562 (chronic myeloid cell line), PC-3 (prostate adenocarcinoma cell line) and 
lymphocytes isolated from healthy blood donors.  
 
Based on the high cytotoxicity observed for Cu-based (Cu and CuO) nanoparticles, 
their toxicity was further explored in Study III. Dose-response relationships as well 
as toxic mechanisms including DNA damage, oxidative DNA damage, cell death 
type, mitochondrial damage and ROS formation were investigated after exposing the 
cultured cells to the nanoparticles. Since previous studies have shown that 
nanoparticles can translocate via the blood to other organs, the HL60 cell line was 
chosen as a model to assess toxicity to blood cells. For comparison, the toxic effects 
of dissolved Cu from the easily soluble CuCl2 were also investigated for comparison 
as several studies have suggested that the toxicity of CuO nanoparticles is partly 
mediated via the release of Cu ions. Finally, particle characteristics including size 
measurements, agglomeration and the release of Cu from the particles were also 
investigated. 
 
In Study IV, amine-modified silica nanoparticles were investigated for their 
biocompatibility and potential use as vectors for gene delivery. Nonporous silica 
nanoparticles were compared to mesoporous silica nanoparticles in their efficiency to 
deliver plasmid DNA in the human breast carcinoma cell line MCF-7. The 
biocompatibility of the nanoparticles was studied using the MTT assay and the 
colony formation efficiency assay. The plasmid DNA delivery efficiency was 
measured using luciferase-encoding plasmid DNA with subsequent measurement of 
luciferase activity. In addition, as the protein corona has been shown to play an 
important role in both toxicity and delivery efficiency of nanoparticles, it was 
investigated how the presence or absence of serum in the cell medium influences 
these features. Particle uptake was studied using transmission electron microscopy 
(TEM). 
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7 METHODS 
This section presents a brief summary of the methods used for assessing the DNA 
damage in the salivary glands, as well as for assessing the toxicity and 
biocompatibility of the nanoparticles, including the particle characterisation methods 
performed by collaborators at the Royal Institute of Technology and the electron 
microscopy unit at Karolinska University Hospital. More detailed information and 
statistical methods can be found in each publication in the appendix. 
 
 
7.1 COMET ASSAY 
The comet assay (also known as single-cell gel electrophoresis) is a method to 
measure DNA damage in cells. Different cell types from blood, tissue or cell cultures 
can be analysed. The alkaline version, first described by Singh et al.149, is the most 
commonly used version to detect strand breaks and alkali-labile sites in the DNA. 
The method can be modified with additional steps of enzyme treatment to detect 
specific DNA lesions. Here, the alkaline version of the comet assay was used to 
detect strand breaks and alkali-labile sites (both together are in the thesis referred to 
as DNA damage). The method was modified with an additional step using FPG to 
enable detection of DNA that has been damaged by oxidation (in this thesis referred 
to as oxidative DNA damage). FPG is a bacterial repair glycosylase which detects 
oxidised purines, mainly 8-oxo-G, but also fapy-G and fapy-A. The enzyme exerts its 
glycosylase activity by cleaving the glycosidic bond between the base and the sugar 
when encountering an oxidised base. This site is then cleaved to an apurinic site due 
to the AP-lyase activity of the bifunctional FPG150. Other lesion-specific enzymes can 
also be used in the comet assay; examples are hOGG1, EndoIII and UNG.  
 
A scheme of the basic steps of the comet assay is shown in Figure 12. The first step 
is to retrieve a single cell suspension. In Study I and II, in which salivary gland tissue 
was analysed, this was achieved by tissue homogenisation using a dounce pestle. In 
Study III cultured cells were used and cell suspensions were obtained after 
centrifugation and resuspension of exposed cells in phosphate-buffered saline (PBS). 
The cell suspensions are then mixed with agarose, spread on microscopic slides and 
the gels are left to solidify on ice. The cells are then put in lysis, during which the 
membranes and cell constituents are broken down, and the structure that remains is 
here referred to as the nucleoid. If specific DNA lesions are to be analysed, the slides 
are then incubated with the specific enzyme, in this thesis FPG, to allow detection 
and creation of apurinic sites at the damaged sites. The apurinic sites are then cut to 
strand breaks, by either lyase activity or during the following alkaline treatment. 
During the alkaline treatment (pH >13), the DNA is unwound and alkali-labile sites 
are hydrolysed to strand breaks. The alkaline treatment is followed by electrophoresis 
during which the strand breaks allow the supercoiled DNA loops to relax and migrate 
from the nucleoid towards the anode. This migration, dependent on the level of DNA 
damage, forms structures resembling comets; with the heads containing supercoiled 
DNA and the tails containing migrated DNA loops. 
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Figure 12. Scheme of the basic steps performed in the comet assay to analyse DNA damage in single 
cells. 
 
To enable visualisation of the comets and quantification of the DNA damage, the 
slides are stained after neutralisation and fixation. Staining in this thesis was carried 
out with ethidium bromide, a fluorescent dye that binds to DNA. Other frequently 
used dyes are SYBR®safe, SYBR®gold and DAPI (4',6-diamidino-2-phenylindole). 
After the staining, the comets can be visualised using a UV-fluorescent microscope 
and the percentage of the amount of DNA in the tail compared to the head can be 
analysed. Other units that can be used to estimate the level of DNA damage are tail 
moment and tail length.  
 
The level of oxidative DNA damage (upon using FPG) is calculated by subtracting 
the value of the non-FPG treated cells, from the value of the FPG-treated cells. 
 
 
7.2 ANALYSIS OF CYTOTOXICITY AND TOXIC MECHANISMS 
A variety of cell viability assays can be used for toxicity testing as well as for 
counting cell numbers for culturing or performing other cell-based assays. The 
following sections briefly present the assays used in this thesis to study cytotoxicity 
and toxic mechanisms of nanoparticles. 
 
7.2.1 Trypan blue exclusion assay 
The trypan blue exclusion assay is a commonly used method to measure cell 
viability. Cells with intact cell membranes are able to exclude the trypan blue dye, 
while damaged cells (non-viable) are not and are therefore stained blue. From 
counting the cells using a microscope, the percentage of dead cells can be calculated 
Single cell 
suspensions!
Lysis!
Enzyme incubation!
Alkaline treatment!
Electrophoresis!
Staining the comets!
Microscopy 
analysis!
FPG!
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as a measure of cytotoxicity. The method was used in this thesis to study the 
cytotoxicity of nanoparticles in Study III.  
 
7.2.2 MTT assay 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) is also a 
commonly used method to assess cell viability. MTT is a colometric assay that 
measures the metabolic activity of cells. The yellow tetrazolium salt is reduced by 
dehydrogenases in the mitochondria to the insoluble and purple formazan. 
Absorbance measurements, using a spectrophotometer, enables assessment of cell 
viability by relating the metabolic activity of cells in exposed populations to 
unexposed populations. The MTT assay was used in Study IV to measure the cell 
viability in MCF-7 cells after exposure to amine-modified silica nanoparticles 
complexed with plasmid DNA.  
 
7.2.3 Resazurin assay 
The resazurin assay (Alamar blue) is another method to evaluate cell viability. The 
dye is converted to fluorescent resorufin upon reduction in metabolically active cells, 
which enables the assessment of cell viability by fluorescence or absorbance 
measurements (less sensitive). This method was applied to assess the cytotoxicity of 
nanoparticles. However, the results showed that some of the nanoparticles interfered 
with the dye (e.g. the ZnO nanoparticles), hence other viability assays were used 
instead. 
 
7.2.4 Annexin V-PI assay 
The above described cell viability assays do not reveal the type of cell death that 
has been induced. The Annexin V-PI assay is a method which enables distinction 
between necrotic and apoptotic cells. Annexin V is a protein with high affinity for 
PS, a membrane phospholipid which is located in the inner leaflet of the cell 
membrane in living cells. Cells undergoing apoptosis expose PS at an early stage of 
the event to the extracellular environment to mark the cell for phagocytosis. By 
using Annexin V conjugated with the fluorochrome FITC, the translocation of PS 
can be detected by flow cytometry. Propidium iodide (PI) is a fluorescent DNA-
binding molecule, which can be excluded by viable cells in contrast to cells with 
damaged cell membrane. That is, when using the Annexin V-PI assay to analyse 
cell death type, viable cells are not stained with any of the dyes, whereas early 
apoptotic cells are stained with FITC-Annexin V, and necrotic and end-stage 
apoptotic cells (with lost cell membrane integrity) are stained with both FITC-
Annexin V and PI. In early necrotic cells are the cells first only stained with PI as 
the PI molecule is smaller and penetrate the cells more easily compared to Annexin 
V. The Annexin V-PI assay was used in Study III to analyse the type of cell death 
induced by Cu-based nanoparticles.  
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7.2.5 Colony formation efficiency assay 
The colony formation efficiency assay is a method to assess cytotoxicity by 
measuring the ability of single cells to form colonies after exposure to any toxic 
agent. These cells are called clonogenic cells. This assay was used in Study IV to 
assess the effect of amine-modified silica nanoparticle on proliferation in MCF-7 
cells.  
 
7.2.6 Mitochondrial damage 
Damaged mitochondria with loss in mitochondrial membrane potential can lead to 
energy depletion, disturbances in the electron transport chain, increased levels of 
oxidative stress and cell death. The fluorescent probe tetramethyl rhodamine methyl 
ester (TMRM) can be used to assess mitochondrial damage. This lipophilic and 
cationic dye accumulates in the mitochondria depending on the mitochondrial 
membrane potential. A loss in mitochondrial membrane potential leads to less 
accumulation of the dye and decreased fluorescence. Incubation with TMRM and 
subsequent FACS analysis was performed in Study III to evaluate the ability of Cu-
based nanoparticles to induce loss of mitochondrial membrane potential.  
 
7.2.7 ROS formation  
One common molecule that can be used to assess ROS in vitro is the 2’,7’-
dichlorfluorescein-diacetate (DCFH-DA) probe. This non-fluorescent molecule can 
easily enter the cell, and once inside it is deacetylated by esterases to DCFH. Upon 
reaction with ROS, the fluorescent compound DCF is formed, which can be detected 
by fluorescence measurements. The oxidation of DCFH can be rapidly performed by 
OH•, RO2• or NO2•, but not by O2-• or H2O2 alone (peroxidases or transition metal 
ions can be used as catalysts)1. DCFH-DA was used in Study III to assess 
intracellular ROS formation after exposing cells to Cu-based nanoparticles.  
 
As it has been shown that ROS can be formed directly on the surface of 
nanoparticles, DCFH-DA was also used in Study III to study ROS formation without 
cells. In this acellular setting, the cleavage of DCFH-DA to DCFH can be performed 
by addition of NaOH prior to incubation with the nanoparticles. 
 
 
7.3 PARTICLE CHARACTERISATION 
7.3.1 Transmission electron microscopy 
Electron microscopy is an imaging technique that uses an electron beam to visualise 
an object. The short wavelength of electrons enables a much higher resolution 
compared to normal light microscopy, which uses photons with longer wavelengths. 
Electron microscopy is therefore extensively used to visualise and obtain information 
on size and shape of nanoparticles. TEM was applied in Study III and IV to visualise 
the Cu-based and silica nanoparticles at dry conditions. TEM was also used in Study 
IV to visualise cellular uptake of silica nanoparticles in the MCF-7 cells.  
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7.3.2 Photon cross-correlation spectroscopy 
In addition to studying the features of nanoparticles under dry conditions, it is also 
necessary to study their behaviour in solution. Nanoparticles tend to group together 
and form agglomerates in solution. Photon cross-correlation spectroscopy (PCCS) is 
a technique using dynamic light scattering (DLS) to study particle hydrodynamic size 
distributions. In PCCS, two laser beams shine onto the sample solution, and the 
Brownian motion of particles in solution, caused by collision with atoms or 
molecules in the liquid, induce fluctuations in the scattering intensities. By analysing 
the fluctuations it is possible to calculate the size of the particles and agglomerates 
over time. DLS was used in Study III and IV to estimate the hydrodynamic sizes of 
the Cu-based nanoparticles and the silica nanoparticles. 
 
7.3.3 Zeta potential 
The zeta potential of particles affects their stability and agglomeration in solution. 
A charged particle in solution is surrounded by ions of opposite charge, forming a 
double layer with strongly bound ions in the inner layer, also known as the Stern 
layer, and more loosely attached ions in the outer layer. This double layer creates 
electrostatical forces upon particle movement. By applying an electrical field and 
measurement of particle velocity, the zeta potential of the particle can be calculated. 
The zeta potential depends on the surface charge of the particles, as well as the 
ionic strength, pH and the composition of the solvent. In Study IV, the zeta 
potential of the silica nanoparticles, with and without complexed plasmid DNA, 
was measured using DLS. 
 
7.3.4 Atomic absorption spectroscopy  
Atomic absorption spectroscopy (AAS) is a technique used to quantify a specific 
element in a sample by volatilising the atoms and subsequently analysing the energy 
absorption spectrum. In Study III, flame AAS was used to measure the amount of 
released Cu from the Cu-based nanoparticles into the cell medium. 
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8 STUDY RESULTS AND DISCUSSION 
 
8.1 STUDY I AND II: DNA DAMAGE AND OXIDATIVE STRESS IN 
CHRONIC KIDNEY DISEASE PATIENTS 
8.1.1 Study I 
Elevated levels of systemic inflammation and oxidative stress are well known in 
CKD patients and implicate a higher risk for cardiovascular disease4. In addition, 
CKD patients often suffer from oral complaints including inflammation in the oral 
cavity, periodontitis, changes in the saliva production and in the saliva 
constituent85,151. Impaired oral health can contribute to systemic inflammation and an 
increased risk for cardiovascular disease. Even though high levels of DNA damage 
and oxidative DNA damage have been previously reported in PBMC from CKD 
patients69,152, studies regarding the DNA damage levels in peripheral tissue, such as 
the salivary glands, are rare. The aim of Study I was to assess the levels of DNA 
damage and oxidative DNA damage in minor salivary glands, and to investigate 
correlation with saliva production, inflammation and uremic markers in CKD 
patients, including both predialysis patients (CKD patients not yet on dialysis) and 
dialysis patients. Salivary glands were studied as they are essential for maintaining a 
good oral health. Damage to the salivary glands can cause decreased saliva 
production, symptoms of dry mouth and increased risk for infections86. The levels of 
DNA damage and oxidative DNA damage were hypothesised to be increased in the 
CKD patients, and the damage to be correlated with hyposalivation.  
 
The results showed that, with regards to DNA damage analysed with the comet 
assay, predialysis patients had significantly higher (p<0.05) levels of DNA damage 
(8.0% DNA in tail, median value) compared to matched controls (6.0% DNA in tail), 
as seen in Table 3. These results are in agreement with previous studies showing 
elevated levels of DNA damage in CKD patients, although in PBMC69,153. The DNA 
damage in predialysis patients was also significantly higher (p<0.001) compared to 
the dialysis patients (5.3% DNA in tail), as seen in Table 3 and in Table 4. In 
similarity, Corredor et al.154 recently observed higher levels of DNA damage in 
PBMC of predialysis patients compared to dialysis patients. An explanation to the 
higher levels of DNA damage in predialysis patients compared to dialysis patients 
may be that the dialysis treatment removes the toxic compounds that can potentially 
induce DNA damage. Indeed, the predialysis patients had significantly higher levels 
of serum urea and leukocyte-particle concentration (LPC) compared to the dialysis 
patients. However, conflicting results have been presented. Schupp et al.155 reported 
that there were no significant changes in DNA damage in PBMC upon initiation of 
haemodialysis, evaluated by both a micronuclei assay and the comet assay. On the 
contrary to our hypothesis, the dialysis patients showed even lower levels of DNA 
damage (5.3% DNA in tail) compared to their matched controls (8.3% DNA in tail). 
These puzzling observations could potentially be explained by a trigger of DNA 
repair mechanisms induced by the increase pro-inflammatory signals as a result of 
the interaction of blood cells with the dialyzer membrane. It was previously shown 
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by Herman et al.156 that spontaneous DNA repair was induced just after dialysis 
treatment in PBMC. 
 
 
 
Median Mean (min–max) n Median Mean (min–max) n Sign.
Age (years) 57 56 (33–66) 10 57 57 (36–69) 10 0.76
DNA strand breaks (%DNA in tail) 8.0 8.9 (5.9–13.8) 10 6.0 6.4 (5.1–9.9) 9 *
Oxidative DNA lesions (%DNA in tail) 8.0 7.9 (2.4–14.4) 10 8.2 7.8 (6.1–10.1) 9 0.87
Secretion rate at rest (mL/min) 0.2 0.3 (0.0–0.9) 10 0.3 0.3 (0.1–0.4) 9 0.653
Secretion rate, stimulated (mL/min) 1.6 1.9 (0.7–4.4) 10 1.8 1.8 (1.1–3.0) 9 0.683
IL-6 in saliva (pg/L) 15.5 16.1 (1.3–40.0) 9 5.0 14.5 (1.6–74.4) 8 0.63
hs-CRP in serum (mg/L) 5.0 10.8 (1.0–67.0) 10 1.0 1.0 (0.0–2.0) 10 **
Orosomucoid in plasma (g/L) 1.1 1.2 (0.8–2.0) 8 0.7 0.7 (0.6–0.9) 10 ***
Haptoglobin in plasma (g/L) 1.4 1.8 (1.0–3.2) 8 0.8 0.7 (0.3–1.1) 10 **
LPC in blood (109/L) 8.5 9.0 (5.6–14.9) 10 6.1 7.5 (5.7–17.2) 10 0.075
Urea in serum (mmol/L) 25.6 26.5 (12.9–36.6) 10 5.8 5.8 (4.9–6.8) 10 ***
Creatinine in serum (µmol/L) 628 626 (341–937) 10 72 73 (54–95) 10 ***
Albumin in serum (g/L) 38 37 (23–48) 10 40 40 (36–43) 10 0.062
Hemoglobin in blood (g/L) 121 119 (92–135) 10 148 148 (126–165) 10 ***
* p<0.05, **p<0.01 and *** p<0.001
Predialysis patients Matched controls
DNA damage
Salivary secretion
Inflammation parameters
Uremic state
 
 
 
 
Median Mean (min–max) n Median Mean (min–max) n Sign.
Age (years) 63 62 (25–87) 69 62 63 (35–89) 69 0.821
DNA strand breaks (%DNA in tail) 5.3 5.6 (3.4–13.2) 59 8.3 8.8 (4.7–18.4) 66 ***
Oxidative DNA lesions (%DNA in tail) 7.6 8.4 (1.4–24.2) 59 8.2 8.6 (0.9–16.7) 66 0.515
Secretion rate at rest (mL/min) 0.1 0.1 (0.0–0.5) 68 0.2 0.3 (0.0–1.4) 69 ***
Secretion rate, stimulated (mL/min) 1.1 1.1 (0.0–2.5) 68 1.7 1.8 (0.3–5.2) 69 ***
IL-6 in saliva (pg/L) 15.0 40.4 (0.2–154.5) 5 5.5 12.9 (0.2–91.5) 53 0.383
hs–CRP in serum (mg/L) 4.5 8.5 (1.0–77.0) 68 2.0 3.4 (1.0–33.0) 68 ***
Orosomucoid in plasma (g/L) 0.9 1.0 (0.4–2.2) 67 0.8 0.8 (0.4–1.2) 68 ***
Haptoglobin in plasma (g/L) 1.2 1.2 (0.1–2.6) 67 1.1 1.1 (0.2–2.4) 68 0.308
LPC in blood (109/L) 6.9 7.1 (1.8–14.6) 69 6.1 6.6 (4.2–14.0) 69 0.059
Urea in serum (mmol/L) 20.5 21.7 (13.3–46.4) 69 5.8 6.0 (3.6–11.2) 67 ***
Creatinine in serum (µmol/L) 716 730 (271–1333) 69 78 79 (48–118) 69 ***
Albumin in serum (g/L) 35 35 (27–44) 68 39 39 (32–46) 69 ***
Hemoglobin in blood (g/L) 125 123 (91–156) 69 146 146 (112–168) 67 ***
***p<0.001
Dialysis patients Matched controls
DNA damage
Salivary secretion
Inflammation parameters
Uremic state
 
 
With regards to the oxidative DNA damage, no significant differences among the 
groups were observed. One could speculate that increased activity of DNA repair and 
antioxidative enzymes are activated upon the enhanced systemic inflammation and 
oxidative stress in the CKD patients. Indeed, Bibi et al.157 showed that peritoneal 
dialysis patients had higher levels of salivary peroxidase and SOD, compared to 
predialysis patients. However, partially in contrast to our findings, antioxidants in 
saliva and serum were shown to be differently affected by peritoneal dialysis. Uric 
acid (an important antioxidant in saliva) and the total antioxidant status, were found 
to be lower in saliva compared to in serum157. The dialysis treatment itself can induce 
ROS formation by activation of neutrophils, which can be caused by a 
bioincompatible dialyzer or contaminated dialysate. It is possible that, since the 
circulating PBMC are in contact with the dialysis membrane, they are triggered to 
release ROS, which can induce activation of the antioxidative defence and DNA 
Table 3. Levels of DNA damage, saliva production, inflammation and uremic markers in predialysis 
patients and matched controls. 
 
 
Table 4. Levels of DNA damage, saliva production, inflammation and uremic markers in dialysis 
patients and matched controls. 
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repair mechanisms in the peripheral tissue. Circulating PBMC and peripheral tissue 
are thus affected differently; while the inflammation and oxidative stress in the blood 
system is elevated, the level in peripheral tissue might be lower or unaffected due to 
the upregulated antioxidative defence or DNA repair mechanisms. However, further 
investigations would be needed to confirm the potentially upregulated repair and 
antioxidative mechanisms, for example by analysis of DNA repair in the salivary 
glands or other peripheral tissue. For a less invasive approach, assessment of 
oxidative stress in the oral cavity can be conducted by analysing 8-oxodG in saliva, 
or potentially by analysing buccal cells using the comet assay. It would also have 
been of value to confirm previous findings of higher levels of DNA damage and 
oxidative DNA damage in PBMC in the present predialysis and dialysis patients. 
 
The salivary secretion rates (both at rest and after stimulation) were, as expected, 
lower in the dialysis patients compared to the matched controls as well as the 
predialysis patients. The salivary secretion rate at rest correlated well to the rate after 
stimulation in both CKD patients and the controls. Previous studies have shown 
similar results, e.g. Gavalda et al.84 showed a significant decrease in stimulated saliva 
production among dialysis patients compared to the controls. Kho et al.158 also 
showed decreased levels of saliva production, both at rest and stimulated parotid 
saliva. Damage to the salivary gland and/or restrictions in fluid intake were proposed 
as underlying factors. Hyposalivation could be an explanation to the higher 
prevalence of oral complaints among CKD patients since the saliva is important for 
lubrication, bacterial defence, buffering capacity, taste and digestion. No significant 
correlation between the salivary secretion rates and DNA damage or oxidative DNA 
damage in the salivary glands was observed. 
 
While all inflammation parameters showed increased levels in the CKD patients 
compared to the matched controls, all observed differences were not statistically 
significant. For example, IL-6 in saliva was only measured in a limited number of 
CKD patients, hence, the difference to the control patients was not statistically 
significant. The uremic parameters, urea and creatinine in serum, were significantly 
higher in both predialysis and dialysis patients compared to the matched controls. In 
contrast, the levels of albumin and haemoglobin were significantly lower in dialysis 
patients compared to the matched controls. Likewise, the levels in predialysis patients 
were also lower compared to the matched controls, although only the difference in 
haemoglobin reached statistical significance. Moreover, there was a significant 
correlation between haptoglobin and oxidative DNA damage in dialysis patients.  
 
It was additionally found that oxidative DNA damage was sex-dependent; women 
had significantly higher levels compared to men in the CKD patient group. That is, 
within the dialysis patients; 9.6% compared to 7.8% DNA in tail and within the 
predialysis patients; 11.9% compared to 7.6% DNA in tail. Age, smoking habits, and 
diabetes were not significantly related to the levels of DNA damage or oxidative 
DNA damage in any of the tested statistical models. 
 
In conclusion, predialysis CKD patients had significantly higher levels of DNA 
damage in minor salivary glands compared to age- and sex-matched controls. On the 
contrary, dialysis patients had significantly lower levels of DNA damage in the minor 
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salivary glands compared to both controls and predialysis patients. No difference in 
oxidative DNA damage was observed. The results suggest that the DNA in salivary 
glands is affected differently by the CKD and the dialysis treatment, compared to 
circulating PBMC. The saliva production, both at rest and stimulated, was lower in 
CKD patients compared to controls. Inflammation and uremic markers were elevated 
compared to controls. There was a correlation between haptoglobin and oxidative 
DNA damage in dialysis patients. No significant correlation between the DNA 
damage or oxidative DNA damage and the salivary secretion rates was observed.  
 
8.1.2 Study II 
In Study II, the effect of dietary supplementation with a sea buckthorn extract was 
studied in CKD patients. A crossover study (2 × 8 weeks, 4-weeks washout) was 
carried out with a patient group including 45 haemodialysis patients. The primary 
outcomes were DNA damage and oxidative DNA damage in the minor salivary 
glands. In addition, saliva production, inflammation and uremic markers were 
studied. The hypothesis was that the supplementation with sea buckthorn extract 
would have beneficial effects on the salivary glands in terms of DNA damage and 
oxidative DNA damage levels, as well as the saliva production. Our hypothesis was 
based on previous studies on sea buckthorn showing antioxidative effects, as well as 
beneficial effects on inflammation and mucous membranes55,56,159. 
 
The results from this intervention study showed that the sea buckthorn 
supplementation did not have significant effects on the levels of DNA damage or 
oxidative DNA damage in the salivary glands. The results are shown in Table 5. The 
median value of DNA damage was 5.2% DNA in tail before the supplementation, 
and 5.1% DNA in tail after the supplementation. The median value of oxidative DNA 
damage was 7.7% DNA in tail before the supplementation, and 8.8% DNA in tail 
after the supplementation.  
 
  39 
Sea buckthorn supplementation
Before After
Mean Median (Min - Max) Mean Median (Min - Max) p
DNA damage
DNA damage (% DNA in tail) 5.5 5.2 (3.4 - 9.4) 5.3 5.1 (3.7 - 8.4) 0.23 a
Oxidative DNA damage (% DNA in tail) 9.1 7.7 (6.4 - 43.5) 8.9 8.8 (5.4 - 13.6) 0.12 a
Saliva production
Secretion rate, at rest (mL/min) 0.1 0.1 (0.0 - 0.6) 0.1 0.0 (0.0 - 0.8) 0.29 a
Secretion rate, stimulated (mL/min) 1.0 0.9 (0.0 - 2.5) 1.0 0.9 (0.0 - 3.0) 0.46 b
Inflammation markers
C-reactive protein (hsCRP) (mg/L) 6.7 4.2 (0.2 - 65.0) 9.4 5.4 (0.4 - 77.2) 0.24 a
Antitrypsin (g/L) 1.5 1.4 (0.9 - 2.3) 1.5 1.5 (0.6 - 2.4) 0.48 b
Orosomucoid (g/L) 1.0 1.0 (0.6 - 2.1) 1.0 1.0 (0.6 - 1.8) 0.55 a
Leukocytes (10^9/L) 7.2 6.8 (1.8 - 14.6) 7.1 6.9 (2.8 - 11.2) 0.93 a
Blood markers
Albumin (g/L) 34.3 35.0 (21.0 - 44.0) 34.3 34.0 (25.0 - 44.0) 0.68 a
Calcium (Albumin corrected) (mmol/L) 2.4 2.5 (1.9 - 1.9) 2.4 2.4 (1.7 - 3.1) 0.43 b
Phosphate (mmol/L) 1.5 1.5 (0.8 - 2.5) 1.7 1.7 (0.9 - 2.7) * b
Potassium (mmol/L) 5.1 5.2 (2.8 - 6.9) 5.0 4.9 (3.2 - 9.6) 0.36 a
Sodium (mmol/L) 138 137 (132 - 146) 139 138 (132 - 146) * a
Creatinine (µmol/L) 746 690 (345 - 1293) 761 765 (384 - 1308) 0.39 b
Urea (mmol/L) 22.2 21.2 (6.0 - 47.8) 22.9 22.8 (8.9 - 39.7) 0.40 a
Carbon dioxide (mmol/L) 24.3 24.0 (15.0 - 32.0) 23.9 24.0 (19.0 - 30.0) 0.39 a
Glucose (mmol/L) 5.9 5.4 (4.1 - 11.0) 5.9 5.4 (2.2 - 11.0) 0.99 a
Haptoglobin (g/L) 1.1 1.0 (0.1 - 2.9) 1.2 1.1 (0.1 - 2.5) 0.30 b
Hemoglobin (g/L) 120 120 (95 - 156) 120 122 (89 - 145) 0.82 b
Thrombocytes (10^9/L) 218 214 (54 - 374) 221 212 (70 - 389) 0.61 b
Transferrin (g/L) 1.8 1.8 (0.8 - 2.7) 1.8 1.8 (1.0 - 2.6) 0.87 b
Immunoglobulin A (g/L) 2.6 2.5 (0.1 - 6.4) 2.7 2.4 (0.1 - 6.3) 0.46 a
Immunoglobulin G (g/L) 11.3 11.0 (4.8 - 21.9) 11.6 10.8 (5.5 - 24.1) 0.13 a
Immunoglobulin M (g/L) 0.7 0.7 (0.1 - 3.5) 0.8 0.7 (0.2 - 3.8) 0.21 a
Iron (µmol/L) 12.0 11.0 (4.0 - 32.0) 10.7 10.0 (5.0 - 25.0) * a
Iron saturation 0.3 0.2 (0.1 - 0.7) 0.2 0.2 (0.1 - 0.6) 0.05 a
a) Non-normal distribution
b) Normal distribution 
*p<0.05
 
A few in vitro studies have previously investigated the effect of sea buckthorn 
extracts on DNA damage. Geetha et al.56 showed that, measured by the comet assay, 
flavones extracted from sea buckthorn decreased the levels of DNA damage induced 
by tert-butyl hydroperoxide in isolated rat lymphocytes. Moreover, radioprotective 
effects of a sea buckthorn extract containing high levels of polyphenols were shown 
by Shukla et al.160 in murine thymocytes. An alkaline halo assay, similar to the comet 
assay, was used and scavenging of ROS induced by the radiation was shown and 
suggested to contribute to the radioprotective effects. 
 
One explanation to the lack of an antioxidative effect on the DNA damage in the 
present study could be that the initial levels of DNA damage actually were lower than 
expected, as observed in Study I. It is possible that analysis of PBMC, in which 
previous studies have shown elevated levels of DNA damage, would have shown 
different results compared to what was observed in the saliva glands. 
 
No significant effects were observed on the saliva production rates, inflammation 
markers and creatinine or urea levels on the supplementation of sea buckthorn. While 
Larmo et al.8 showed a significant effect of sea buckthorn on CRP levels (median 
reduction was -0.059 mg/L), no significant changes in the inflammation markers 
were seen in the present study. The conflicting results may be a result of differences 
Table 5. Effects of eight weeks of dietary supplementation with a sea buckthorn oil extract on 
DNA damage, saliva production, inflammation and blood markers in haemodialysis patients. 
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in the supplement content; in the study by Larmo et al., sea buckthorn puree, with 
higher content of water-soluble compounds was supplemented. In another study by 
Larmo et al.9, an attenuation of increased tear film osmolarity was detected after 
administration of sea buckthorn. Even though no changes in the fatty acid content of 
the tear film were detected, a mechanism involving modulation of the local 
inflammation status of dry eyes was proposed. 
 
Although the differences were small, the phosphate and sodium levels significantly 
increased after sea buckthorn supplementation, from 1.5 and 137 mmol/L to 1.7 and 
138 mmol/L, respectively, after the supplementation (p=0.02 for both phosphate and 
sodium). Sodium is an important osmolyte where alterations in the serum levels of 
sodium could have an impact on osmosis and cellular functions. Increased phosphate 
levels are also potentially harmful as hyperphosphatemia stimulates the vascular 
calcification, a risk factor for developing atherosclerosis and cardiovascular 
disease161. Iron was significantly (p=0.05) reduced after supplementation, from 11.0 
to 10.0 mmol/L. Since iron is important for oxygen transport, and iron deficiency can 
lead to anaemia, the observed reduced effect is potentially harmful. However, the 
changes were small and may not be of clinical relevance. 
 
Dietary supplementation with sea buckthorn has not been studied in CKD patients 
previously. However, there are a few studies that have investigated other fruit and 
berry juice or extracts; one example is a recently presented crossover study on the 
effects of pomegranate supplementation on oxidative stress, inflammation and serum 
lipids in haemodialysis patients. Neither the biomarkers for oxidative stress (plasma 
F2 isoprostanes and isofuranes), the inflammation markers (CRP and IL-6), nor lipid 
profiles were affected162. On the contrary, a study by Shema-Didi et al.163 showed 
that one year of intake of pomegranate juice had positive effects in haemodialysis 
patients, with ameliorated levels of investigated biomarkers for oxidative stress and 
inflammation (including oxidation protein products, malondialdehyde, IL-6 and 
TNF-α) compared to the placebo juice. 
 
In Study II, the placebo treatment did in fact affect some of the measured parameters, 
as seen in Table 6. There was a significant increase in creatinine (p=0.030) and urea 
(p=0.009) levels, as well as immunoglobulin A (p=0.04) and M (p=0.01), while the 
CO2-level decreased after the placebo treatment (p=0.004). The placebo capsules 
contained coconut oil, which is a commonly used placebo oil in studies on fatty acid 
supplementation. Since creatinine and urea accumulate in blood when kidney 
function is impaired, these findings suggest that a different placebo substance should 
be used in future intervention studies in CKD patients. 
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Placebo treatment
Before After
Mean Median (Min - Max) Mean Median (Min - Max) p
DNA damage
DNA damage (% DNA in tail) 5.5 5.2 (3.6 - 13.2) 5.9 5.3 (3.6 - 11.5) 0.20 a
Oxidative DNA damage (% DNA in tail) 9.0 8.8 (4.6 - 24.2) 8.6 8.2 (4.1 - 13.7) 0.89 b
Saliva production
Secretion rate, at rest (mL/min) 0.1 0.1 (0.0 - 0.5) 0.1 0.1 (0.0 - 0.9) 0.23 a
Secretion rate, stimulated (mL/min) 1.1 1.1 (0.0 - 2.4) 1.1 0.9 (0.0 - 3.3) 0.97 a
Inflammation markers
C-reactive protein (hsCRP) (mg/L) 10.1 5.0 (0.4 - 77.0) 9.0 4.5 (0.2 - 95.9) 0.63 a
Antitrypsin (g/L) 1.5 1.6 (0.8 - 2.1) 1.5 1.5 (0.7 - 2.1) 0.37 b
Orosomucoid (g/L) 1.1 1.0 (0.4 - 2.0) 1.0 1.0 (0.6 - 1.6) 0.31 a
7.1 7.1 (2.6 - 7.1 6.8 (3.3 - 12.6) 0.82 b
34.4 34.0 (22.0 - 43.0) 34.6 35.0 (25.0 - 41.0) 0.60 b
2.4 2.5 (2.1 - 2.9) 2.5 2.5 (2.2 - 2.7) 0.43 b
1.7 1.6 (0.9 - 3.2) 1.8 1.8 (0.9 - 3.1) 0.46 a
5.0 4.9 (3.1 - 6.6) 5.4 5.4 (3.7 - 8.4) * b
138 138 (131 - 150) 138 138 (128 - 143) 0.54 b
719 693 (346 - 1078) 774 751 (400 - 1402) * b
21.8 22.0 (8.2 - 40.0) 24.5 24.6 (10.9 - 54.3) ** a
24.4 24.0 (20.0 - 29.0) 23.1 24.0 (14.0 - 29.0) ** a
6.0 5.4 (4.2 - 11.0) 6.3 5.2 (3.9 - 20.2) 0.40 a
1.3 1.2 (0.1 - 2.7) 1.2 1.2 (0.1 - 2.7) 0.61 b
120 121 (94 - 149) 123 123 (91 - 159) 0.27 b
213 189 (59 - 343) 211 204 (106 - 395) 0.81 a
1.8 1.8 (1.1 - 2.6) 1.8 1.8 (1.1 - 2.9) 0.15 b
2.7 2.6 (0.1 - 5.6) 2.8 2.5 (0.1 - 6.3) * b
11.2 10.7 (4.9 - 22.0) 11.4 10.9 (5.4 - 5.4) 0.33 b
0.7 0.7 (0.1 - 3.2) 0.8 0.7 (0.1 - 3.6) ** a
12.2 11.0 (5.0 - 38.0) 11.4 10.0 (7.0 - 22.0) 0.74 a
0.3 0.2 (0.1 - 0.7) 0.3 0.2 (0.1 - 0.6) 0.73 a
a) Non-normal distribution
b) Normal distribution 
*p<0.05, **p<0.01
11.0)
Thrombocytes (10^9/L)
Transferrin (g/L)
Immunoglobulin A (g/L)
Immunoglobulin G (g/L)
Phosphate (mmol/L)
Iron (µmol/L)
Sodium (mmol/L)
Blood markers
Creatinine (µmol/L)
Iron saturation
Urea (mmol/L)
Immunoglobulin M (g/L)
Potassium (mmol/L)
Hemoglobin (g/L)
Leukocytes (10^9/L)
Carbon dioxide (mmol/L)
Glucose (mmol/L)
Haptoglobin (g/L)
Albumin (g/L)
Calcium (Albumin corrected) (mmol/L)
 
The study design might also have had an impact on the results. A crossover study has 
the advantage of acquiring fewer study subjects since the patients are their own 
controls. This design also decreases the influence of variation in the disease state of 
the patient and covariates. The design is based on the assumptions that the disease 
condition is stable during the study period, and that the period is short enough to 
avoid period effects such as seasonal variations. In addition, the effect of the 
intervention should not be permanent and the wash-out period between the treatment 
periods should be long enough to prevent carry-over effects. Violations of the 
assumptions may result in incorrect data analysis. In the present study, the kidney 
disease was assumed to remain stable during the study period of total 20 weeks. 
However, period effects of some parameters, including CO2, potassium, calcium-
phosphate product and calcium levels were observed. Further, despite a wash-out 
period of four weeks, a carry-over effect on iron levels was found. However, the 
statistical analysis carried out in this thesis was not corrected for multiple 
comparisons. If adjustments on p-values had been carried out, a majority of the 
period effects had not been statistically significant. Crossover studies are also more 
sensitive to drop-outs compared to parallel study designs since paired analysis is 
performed. The study in this thesis had 16 drop-outs, due to acute illness, non-
compliance and deaths, which limited the output of the study. It should also be noted 
Table 6. Effects of eight weeks placebo treatment on DNA damage, saliva production, inflammation 
and blood markers in haemodialysis patients. 
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that sea buckthorn is rather sour, which can result in increased study dropouts. In a 
study by Eccleston et al.164, 33% of the study participants dropped-out due to gastro-
intestinal intolerance of the sea buckthorn and the placebo juice. A majority of the 
participants completing that study reported the addition of sweetener to improve the 
taste. No significant effects on risk factors for coronary heart disease were 
observed164. 
 
A limitation of Study I was the lack of measurement of the actual levels of the 
supplemented nutrients (the fatty acids and the vitamin A and E) in the study objects. 
Both baseline values as well as levels after treatment would have been valuable 
information for interpreting the study results. 
 
Even though some of the previously published studies on sea buckthorn were in vivo 
studies, the majority of the previous findings on antioxidative effects were performed 
in cultured cells. The present results point out the limitations in extrapolating in vitro 
findings to in vivo systems. As stressed by Halliwell165, cultured cells are in many 
ways different from cells in vivo. Cultured cells are often cancer cells and divide 
more rapidly compared to non-cancerous cells. Cultured cells are also exposed to 
higher levels of oxidative stress, caused by increased ROS due to elevated oxygen 
tension, and due to possible lower levels of antioxidants such as vitamin C and E in 
the cell culture medium165. In addition, some cell culture media contain added salts of 
transition metals, of which the metal ions can generate ROS. Studies on oxidative and 
antioxidative effects in cultured cells must therefore be carefully designed and 
interpreted.  
 
Study II further points out the contradictions in dietary supplements versus dietary 
intake of fruits and vegetables. The dietary antioxidants are thought to protect the 
biomolecules from oxidative damage, and thereby lower the risk for disease. 
Focusing on the damage to the DNA, the antioxidative protection is thought to lower 
the risk for cancer. However, taking in to account the results from Study I and Study 
II, and previous studies on dietary supplementation, it is reasonable to conclude that 
the endogenous antioxidative systems play a more significant role in 
preventing/repairing damage to cellular molecules compared to added antioxidants in 
supplements.  
 
In conclusion, dietary supplementation with a sea buckthorn extract did not affect the 
levels of DNA damage and oxidative DNA damage in the minor salivary glands of 
haemodialysis patients. No improvements of saliva production, inflammation or 
uremic markers were observed.  
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8.2 STUDY III AND IV: TOXICITY AND BIOCOMPATIBILITY OF 
NANOPARTICLES 
The aims of the second part of this thesis were to identify particularly toxic, as well 
as biocompatible, nanoparticles and to further examine toxic mechanisms and 
possible applications.  
 
8.2.1 Particle screening 
The aim of this pre-study was to screen a range of different nanoparticles for their 
cytotoxicity and to further compare the cytotoxicity of a selection of nanoparticles in 
different cell types. Initially, 37 different nano- and microsized particles with varying 
composition were screened for their cytotoxicity towards A549 lung cells. The results 
showed that certain nanoparticles were more toxic compared to others, while several 
nanoparticles did not induce any cytotoxicity, see Figure 13. The results 
demonstrated that the chemical composition is important in nanotoxicology and that 
all nanoparticles are not necessarily cytotoxic. However, it should be noted that the 
screening was performed using one concentration at one exposure time point and in 
one cell line. The Cu-based particles, especially the nanosized particles, showed 
particularly high cytotoxicity. Zn-based nanoparticles did also show cytotoxicity, 
which was further explored in the HL60 cell line in a study not included in this thesis. 
Silicon dioxide (SiO2), also known as silica, and iron-based nanoparticles showed 
low cytotoxicity, thus, both particle types are attractive for biomedical applications. 
Owing to the feasibility of surface modifications and their biocompatibility, silica 
nanoparticles are used for example in implants, surface coatings and as delivery 
vectors for drugs or genes. The latter was further explored in Study IV. Iron oxide 
nanoparticles with superparamagnetic properties hold great promises for applications 
including contrast agents in magnetic resonance imaging (MRI), drug/gene delivery, 
multimodal imaging and biosensors166. However, conflicting results on the toxicity of 
both iron oxide nanoparticles167 and silica nanoparticles168 have been published. 
Therefore, caution should be taken when using these particles in applications with 
potential human exposure.
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Figure 13. C
ytotoxicity of 37 nano- and m
icroparticles in A
549 cells, m
easured by trypan blue staining after 18 h exposure to a particle concentration of 80 µg/m
L. 
U
npaired tw
o-tailed Student’s t-test w
as perform
ed to com
pare significant differences betw
een each particle exposure and control. * represents p<0.05, **p<0.01 and  
***p<0.001, respectively. 
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Figure 14. Comparison of size-dependent cytotoxicity of particles of Cu, CuO and Fe3O4 after 
exposing A549 cells to particle concentrations of 80 µg/mL for 18 h. Evaluated by trypan blue staining 
and one-way ANOVA analysis (followed by Tukey HSD post hoc test for the Cu particles). The size 
information was retrieved from to the manufacturers of the particles. A) Size-dependent effect 
(p=0.002) of three Cu particles with the sizes  45 µm, 100 nm and 50 nm respectively. B) Size-
dependent effect (p<0.001) of two CuO  particles with the sizes 3 µm and 42 nm. C) No observed size-
dependent effect of Fe3O4 particles.  
 
Size-dependent effects were observed for both Cu and CuO particles, with the 
smaller particles being more cytotoxic, as seen in Figure 14. The results are in 
agreement with previous studies showing that CuO nanoparticles are more toxic 
compared to microsized CuO particles in A549 cells169,170. Increased cytotoxicity and 
increased levels of DNA damage induced by the CuO nanoparticles were presented 
in these studies. The observed enhanced toxicity of nanoparticles compared to 
microparticles is often explained by a larger surface area and a higher surface 
reactivity. However, as can also be seen in Figure 13 and Figure 14, no apparent 
differences in toxicity between nano- and microsized particles of Fe3O4, Fe2O3, TiO2 
and SiO2 were observed.  
 
After screening for particle toxicity, the next step was to investigate different cell 
types in their susceptibility towards nanoparticles. A selection of nanoparticles was 
investigated in six different cell types (A549, K562, HL60, Jurkat, PC-3 and isolated 
lymphocytes). One key finding was the great variety in the toxic response among the 
different cell types after particle exposure, as shown in Figure 15. The response 
differences were most pronounced for CuO, ZnO and Ag nanoparticles. Interestingly, 
the Ag nanoparticles were more toxic towards the isolated lymphocytes compared to 
the transformed cells of the different cell lines. This is alarming since Ag 
nanoparticles are widely used in many consumer products, e.g. for anti-odour effects 
in sports clothing. A review on biological effects on Ag nanoparticles was recently 
presented by Bartlomiejczyj et al.171. The toxicity of Ag nanoparticles was not further 
investigated in this thesis. The cell lines and the lymphocytes clearly differ from each 
other, since the cell lines are transformed cells and have therefore different cell 
signalling and cell death mechanisms compared to normal cells. In addition, varying 
mechanisms for cellular uptake, internalisation and intracellular fate of particles, 
depending on the cell type, can also influence the toxicity132. The importance of cell 
type selection was previously stressed by Bregoli et al.172 who investigated the 
toxicity of Sb2O3 nanoparticles in hematopoietic progenitor cells from healthy donors 
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as well as in seven different hematopoietic cell lines. The authors reported that Sb2O3 
nanoparticles inhibited the proliferation of erythroid progenitors but not granulocytic-
monocytic progenitors from healthy donors. In addition, while the nanoparticles 
showed no adverse effects on proliferation in the cell lines, the differentiation of 
THP-1 cells (monocytic leukaemia cells) into macrophages was inhibited, which led 
to cell death. In this thesis, both lymphocytic Jurkat cells (T-lymphoblastic cells) and 
myelocytic cells (HL60 cells that are acute myeloid leukaemia cells and K562 cells 
that are chronic myeloid leukaemia cells) were studied. The differences in the toxic 
response between these cell lines were small. However, particularly upon exposure to 
CuO nanoparticles, certain differences became more prominent. A549 and PC-3 cells 
were shown to be more sensitive compared to the other cell types. Both A549 and 
PC-3 are epithelial cells, and they are adherent cells whereas HL60, K562 and Jurkat 
cells grow in suspension, which potentially affects the delivered dose to the cells and 
hence the toxic response. Differences among cell types in cellular uptake 
mechanisms or metabolic activity, may also explain the diversity in the toxic 
response, as discussed by Lanone et al.173 and Chang et al.174. Differences in the 
contents of different cell media used for the adherent cells (DMEM) and the 
suspensions cells (RPMI) may also influence the toxicity. Therefore, these findings 
highlight the importance of the appropriate choice of cell type for nanotoxicology 
investigations. 
 
 
 
Figure 15. Cytotoxicity of seven selected nanoparticles in five different cell lines, and PBMC isolated 
from healthy blood donors. Measured by trypan blue staining after 18 h exposure to particle 
concentrations of 80 µg/mL. 
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8.2.2 Study III 
In Study III, the mechanisms of the toxicity of Cu-based nanoparticles were further 
investigated in the myeloid HL60 cell line. Even though Cu is an essential trace 
element, excess levels may disturb the Cu homeostasis and lead to ROS formation 
via Fenton reactions, or dysfunctional enzymes175. Previous toxicity studies on Cu-
based nanoparticles have mostly focused on epithelial cells. Since it has been shown 
that nanoparticles can translocate to the circulatory system, the HL60 cells were 
applied as a model for blood cells. The study focused on the effects of Cu and CuO 
nanoparticles on the cell viability, mitochondrial damage, DNA damage and 
oxidative DNA damage as well as the formation of ROS. As previous studies have 
proposed that the toxicity of CuO nanoparticles is caused by extra- or intracellular 
dissolution, toxic effects of dissolved Cu from easily soluble CuCl2 were also 
investigated. In addition, particle characteristics including size, agglomeration and 
dissolution were investigated. 
 
The results showed that both Cu and CuO nanoparticles were cytotoxic in the HL60 
cells. The Cu nanoparticles showed high cytotoxicity at considerably lower 
concentrations compared to the CuO nanoparticles. Dose-response relationships were 
investigated and showed that the Cu nanoparticles were most toxic, followed by the 
Cu ions and lastly the CuO nanoparticles, as seen in Figure 16. The observed low 
toxicity of the CuO nanoparticles compared with the Cu ions differs from previous 
findings, in where CuO nanoparticles have been shown to be far more toxic in 
comparison with Cu ions135,136,169. In certain studies, the higher toxicity of CuO 
nanoparticles compared to Cu ions has been explained by a Trojan horse-type 
mechanism135,136. That is, the particulate form of CuO enables cellular uptake via 
endocytosis, and particle dissolution inside the cell can give rise to increased levels of 
Cu ions. The entrance of free ions from the extracellular environment into cells is 
normally regulated by metal sensing and transport proteins134.  
 
 
 
Figure 16. Dose-response relationships of Cu and CuO nanoparticles as well as CuCl2 at equivalent 
copper concentrations in HL60 cells after 18 h exposure, evaluated by trypan blue staining, n=3. 
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The results in the present study demonstrated that HL60 cells are less sensitive to 
CuO nanoparticles compared to A549 cells, which could potentially be explained by 
differences in cellular uptake mechanisms. It is likely that A549 cells, which are 
epithelial cells, exert more endocytic activity compared to the HL60 cells. By 
comparing the toxicity of Cu, CuZn and CuO nanoparticles in A549 cells and HL60 
cells, a greater difference in the toxic response between the two cell types was 
observed for the CuO nanoparticles in comparison with the Cu and CuZn 
nanoparticles, as shown in Figure 17. Karlsson et al.176 showed that Cu and CuZn 
nanoparticles are more membrane reactive and induced more membrane damage 
compared to CuO nanoparticles. Hence it is possible that the toxicity of Cu 
nanoparticles is not as dependent on cellular uptake as the CuO nanoparticles, which 
can explain the lower variation in toxicity of Cu nanoparticles among different cell 
types. Further investigation on cellular uptake and cellular dose would nonetheless be 
necessary to support this theory. For instance, careful evaluation using endocytotic 
inhibitors such as chlorpromazine to study clathrin-mediated uptake, filipin and 
nystatin to study caveolae/lipid graft-mediated uptake or cytochalasin D to study 
actin-dependent uptake, could be conducted to obtain information on the cellular 
uptake mechanisms177. Furthermore, comparison of the particle characteristics in the 
different cell media used would be necessary. 
 
 
 
 
Figure 17. Comparison of cytotoxic effects of Cu, CuZn and CuO nanoparticles in A549 and HL60 
cells, measured by trypan blue staining after 18 h exposure to particle concentration of 80 µg/mL, n=3. 
 
Since oxidative stress has been proposed as one of the key toxicological mechanisms 
of nanoparticles, the oxidative effects of the Cu-based nanoparticles were evaluated 
using three strategies. The formation of ROS was initially studied in an acellular 
system in order to evaluate whether the nanoparticles were able to generate ROS 
intrinsically. Further, the intracellular ROS formation, as well as oxidative DNA 
damage, was studied in the HL60 cells. The results showed that the Cu nanoparticles 
induced high levels of ROS in the acellular setting. The intracellular levels of ROS 
induced by the Cu nanoparticles were slightly elevated, however the standard 
deviations were large. The DNA damage and the oxidative DNA damage showed a 
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tendency to be increased after exposure to Cu nanoparticles. While CuO 
nanoparticles did not induce acellular or intracellular ROS, or oxidative DNA 
damage, the Cu ions (CuCl2) increased the acellular levels of ROS, but neither 
intracellular ROS nor oxidative DNA damage was observed. The results differ from 
previous findings where higher levels of intracellular ROS and oxidative stress have 
been reported upon exposure to CuO nanoparticles. For example, Siddiqui et al.178 
showed, after exposing HepG2 cells to CuO nanoparticles, a dose-dependent increase 
in lipid peroxidation and a dose-dependent decrease in glutathione levels. The authors 
also showed that N-acetyl-cystein protected against cell death, indicating oxidative 
stress-mediated cytotoxicity.  
 
The effect of the Cu-based nanoparticles on the mitochondria was investigated using 
TMRM. Mitochondrial depolarisation was observed already after 2 h exposure to Cu 
nanoparticles, while the CuO nanoparticles and the Cu ion, did not induce any 
observed changes during the first 6 h of exposure. After a longer exposure time  
(24 h), all exposure concentrations induced mitochondrial depolarisation. These time-
dependent effects may be explained by the fact that Cu nanoparticles react more 
rapidly with the cell membrane, whereas the toxicity of CuO nanoparticles may be 
more dependent on cellular uptake and subsequent dissolution, as discussed above. 
 
As analysed by Annexin V-PI staining, the main type of cell death appeared to be 
necrosis for both Cu and CuO nanoparticles, as well as for CuCl2. However, further 
investigations are required to confirm the cell death type as the analysis was only 
performed at one exposure time point (18 h). It cannot be excluded that apoptotic 
processes are involved at earlier stages of the exposure. 
 
The differences in toxicity profiles of Cu and CuO nanoparticles can potentially be 
explained by the different chemical compositions and dissolution profiles of the 
materials. Cu nanoparticles are composed of a metallic Cu core, which is covered by 
a thin oxide surface of Cu2O and CuO. CuO nanoparticles are instead homogenously 
composed of CuO179. This difference in the composition will influence the metal 
release processes from these particles; the release from the Cu nanoparticles is 
governed by chemical and electrochemical processes, whereas the release from the 
CuO nanoparticles is governed by chemical processes. It is thus possible, that the 
high levels of ROS induced by Cu nanoparticles in the acellular assay, in Study III, 
are due to the electrochemical and chemical dissolution of Cu nanoparticles. In these 
processes both Cu(I) and Cu(II) are released, which can take part in redox reactions. 
In a previous study Li et al.180 proposed that the observed toxicity of Cu 
nanoparticles in E.coli was caused by the generation of H2O2, mediated by the release 
of Cu(I). The importance of the valence state of the released ions on the toxicity was 
stressed, and it was suggested that the toxicity of Cu nanoparticles was independent 
on Cu(II), explaining the observed lower toxicity of CuCl2180. 
 
Investigation of the released amount of Cu ions into cell media using AAS, showed 
that the release was fast and started directly after the sonication of the Cu 
nanoparticles dispersions, whereas the release from the CuO nanoparticles was 
slower. This difference in metal release kinetics may, together to the difference in 
oxidation state of the released species, explain the higher cytotoxicity observed for 
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Cu nanoparticles compared to CuO nanoparticles. It is also likely that the release of 
Cu ions from the Cu nanoparticles is enhanced upon contact with the cells, since the 
cell membrane contains three times more oxygen compared to the cell medium, as 
discussed by VanWinkle et al.181. An interesting further investigation of this study 
would be to examine the released species from the particles, including evaluation of 
the oxidation state as well as the complexation products that are likely to be formed 
between the ions and cell medium constituents182. 
 
In addition to the intrinsic properties of nanoparticles, several methodological settings 
affect the outcome of studies on biological interactions of nanoparticles. This 
includes the preparation of the nanoparticles prior to the cell exposure, e.g. the 
sonication and the presence or absence of serum in the cell medium. Sonication, 
using an ultrasonic probe or bath, is a commonly applied procedure to disperse 
particles in cell medium prior cell exposure. Fetal bovine serum is often added to cell 
culture medium as growth factor supplementation. In a study by Cronholm et al.183, it 
was shown that sonication increased the cytotoxicity of Cu nanoparticles, whereas 
the presence of serum in the cell culture media increased the Cu release, but did not 
affect the cytotoxicity. In fact, Kim et al.184 showed that increased levels of serum 
suppressed the cytotoxicity induced by amine-modified polystyrene nanoparticles. 
Differences in the sonication procedures as well as the use of different serum content 
and levels may explain the contradictory results often reported from different studies. 
 
Moreover, careful evaluation and relevant controls should be considered when 
choosing the assay for studying nanoparticle toxicity. Several nanoparticles have 
been shown to interfere with commonly used viability assays based on 
spectrophotometric analysis185,186. Interference with the resazurin assay was observed 
for ZnO nanoparticles in the present investigation. The trypan blue exclusion assay 
was therefore used to evaluate cell viability. The trypan blue-stained cells were 
counted manually under a light microscope and potential optical interferences are 
thus diminished. However, this method has the disadvantage of being rather time-
consuming and less sensitive, as only the late stages of the cell death is detected187. It 
should also be noted that the disability of a cell to exclude the trypan blue dye does 
not necessarily mean that the cell is dead; it is rather a measure of the cell membrane 
integrity188. Thus, the results from the trypan blue assay were compared with the 
results from a second cell death analysis assay, the Annexin V-PI assay, where good 
correlation between the methods was observed for CuO nanoparticles, while a 
notable discrepancy was observed for the Cu nanoparticles. While the trypan blue 
assay showed a higher cytotoxicity of the Cu nanoparticles compared to the Annexin 
V-PI assay, underestimation of the cytotoxicity using the trypan blue assay would 
have been more probable, since the trypan blue molecule is larger compared to the PI 
molecules used in the Annexin V-PI assay and hence is more easily excluded by the 
cells.  
 
The lack of evaluation of endotoxin contamination of the nanoparticles is a limitation 
of the study. Due to the reactive surface of nanoparticles, molecules including 
endotoxins can easily be adsorbed to the surface. Contamination of nanoparticles can 
give rise to misinterpretation of toxicological data, both in vitro and in vivo.  
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In conclusion, the results from the particle screening and Study III showed that Cu-
based nanoparticles were cytotoxic. The toxic response varied among different cell 
types, potentially due to different uptake mechanisms. Cu nanoparticles revealed 
higher cytotoxicity compared to CuO nanoparticles and CuCl2 in the HL60 cells. The 
Cu nanoparticles induced high oxidation in an acellular setting, as well as slightly 
increased levels of intracellular ROS and oxidative DNA damage. CuO nanoparticles 
did not induce acellular ROS and the intracellular ROS and DNA damage was 
limited. Differences in the metal release processes might explain the different toxicity 
profiles of the Cu and CuO nanoparticles. 
 
8.2.3 Study IV 
Silica nanoparticles offer several exciting opportunities for usage in nanomedicine, 
owing to the feasibility in designing the particles with a desired function, as well as 
their low intrinsic toxicity. For example, particles with porous structure can be 
produced, and the size and pore volume can be adjusted to increase the drug/gene 
loading capacity and to control cargo release processes189. In Study IV, nonporous 
and mesoporous forms of silica nanoparticles, modified with propylamine-groups, 
were investigated for their biocompatibility and ability to deliver plasmid DNA in 
MCF-7 breast carcinoma cells. Thorough investigation of the physicochemical 
properties, as well as the influence of serum in the cell medium was performed as 
these factors have been shown to strongly affect the interactions of nanomaterials 
with biological systems. 
 
The surface charge of nanoparticles is an important physicochemical property that 
has a great impact on the biological interactions. Therefore, DLS measurements were 
performed to calculate the zeta potential, which provides information regarding the 
surface charge of the particles. It should however be noted that the zeta potential is 
affected by both the surface charge of the particles, as well as the solvent, which in 
this study was DMEM. Both the nonporous and the mesoporous amine-modified 
particles were shown to have a slight positive charge in DMEM (without added 
serum), with the latter showing less positive charge. According to the manufacturer, 
the particles have been modified with the same amount (wt%) of propylamine. The 
mesoporous particles should therefore have a lower amount of amine-groups on the 
external surface (not including the pores), which would explain the less positive 
charge compared to the nonporous particles. Delivery vectors are commonly cationic 
to facilitate the complexation of the particles with the negatively charged DNA, and 
to enable the following cellular internalisation. Positively charged particles attach 
more easily to the anionic hydrophilic cell membrane and are in general also taken up 
by cells more readily190. Consequently, cationic particles are generally also more 
cytotoxic compared to neutral or negatively charged particles191. A neutral charge of 
the particle and DNA complex is favourable for in vivo applications, in order to avoid 
interaction with blood components and prolong the blood circulation time192. Surface 
modifications with polymers such as PEG can be used to mask the particle charge 
and increase the hydrophilicity, and thereby prevent unspecific protein 
interactions107. In Study IV, the surface charge of the nonporous and the mesoporous 
particles became slightly negative upon DNA complexation. Cellular uptake was 
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studied by TEM and the silica nanoparticles were internalised in agglomerates, as 
shown in Figure 18. 
 
 
 
Figure 18. TEM images of MCF-7 cells exposed to mesoporous silica nanoparticles. Photo by Kjell 
Hultenby. 
 
The delivery efficiency was higher for the nonporous silica nanoparticles compared 
to the mesoporous particles. This was observed both with and without serum in the 
cell medium. The delivery efficiency of both particles in the presence of serum is 
shown in Figure 19. The pore size of the mesoporous particles was relatively small 
(2.4 nm), which is a likely explanation of their poor delivery efficiency as the 
plasmid DNA was too large to be loaded in the pores. In general, particles with small 
pore size are suitable for encapsulating smaller drug molecules in the pores, 
potentially combined with larger biomolecules such as DNA and RNA, adsorbed or 
anchored on the external surface193. However, DNA is vulnerable to enzymatic 
degradation, which is a challenge to overcome for in vivo applications. This can be 
solved by using particles with larger-sized pores that are more suitable for gene 
encapsulation within the pores194,195. Kim et al.194 showed that mesoporous silica 
nanoparticles with ultralarge pores (23 nm pore size) were superior in plasmid DNA 
delivery efficiency in HeLa cells, compared to those with small pores (2 nm pore 
size). Ultralarge pores also improved the delivery of small interfering RNA (siRNA), 
both in vitro and in vivo, compared to silica particles with smaller pores195. The 
siRNA was also protected from enzymatic degradation when the particles with 
ultralarge pores were used. Thus, increasing the pore size might be a possible 
approach to improve the delivery efficiency of silica nanoparticles.  
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Figure 19. Delivery efficiency of nonporous (NSP) and mesoporous (MSP) silica nanoparticles 
complexed with luciferase-encoding plasmid DNA (pDNA) at different weight ratios. n=3.  
 
The greater delivery efficiency of the nonporous compared to the mesoporous 
particles could, in parallel with the difference in surface charge of the particles, be 
explained by the higher external surface area of the nonporous particles. 
Functionalisation of the particles with propylamine groups to the same extent (wt%) 
would lead to a larger amount of amine-groups present at the external surface of the 
nonporous particles, as a considerable part of the amine groups is present within the 
pores of the mesoporous particles196. As a result, the actual binding of the DNA is 
decreased for mesoporous particles as is the interaction with the cell and the cellular 
uptake. As suggested by Slowing et al.196, this smaller external surface area of porous 
silica particles can decrease their interaction with cell membranes of red blood cells 
and thereby reduce their haemolytic activity.  
 
The delivery efficiency of the both tested types of silica nanoparticles was anyhow 
considerably lower compared to the commercially available in vitro transfection 
agent Lipofectamine 2000, which gave a relative light unit (RLU)/cell viability of 
1×106. Approaches to further increase the delivery efficiency of silica nanoparticles 
include functionalisation using polyethyleneimine (PEI)197 and cell penetrating 
peptides198. Recently, Brevet et al.106 reported improved plasmid DNA delivery 
efficiency in vitro, using histidine-functionalised silica nanoparticles in comparison 
to amine-modified silica nanoparticles. However, in vivo, both particles showed 
similar efficiencies. 
  
Both of the studied amine-modified silica nanoparticles showed excellent 
biocompatibility, i.e. the toxicity was low. The biocompatibility of the complex of 
particle and plasmid DNA was studied using the MTT assay, and the 
biocompatibility of the silica nanoparticle vectors alone were studied using the CFE 
assay. The nonporous silica particles showed slightly higher toxicity compared to the 
mesoporous particles in the absence of serum in the cell culture medium, as shown in 
Figure 20A and Figure 20C. These findings are in line with previous studies, where 
nonporous silica particles were found to be more toxic compared to porous 
particles196,199. Interestingly, the toxicity of the porous silica particles was abolished 
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in the presence of serum, as shown in Figure 20B and Figure 20D. This is promising 
for in vivo applications as the presence of serum mimics better the conditions in 
biological fluids. Upon contact with biological fluids, or cell culture medium, 
proteins and other biomolecules will cover the surface of the nanoparticles, forming a 
protein corona200. The nature of the corona depends on the size and surface properties 
of the particle, but also on the composition of the solvent. The corona dictates at least 
the initial particle-cell interactions, including the cellular uptake and toxicity. It is 
generally considered that the protein corona leads to a decreased toxicity. However, 
its impact on the toxicity depends on the property of the particle. It has, for example, 
previously been shown that the protein corona on silica nanoparticles reduces their 
cytotoxicity and their haemolytic activity148,201. On the contrary, for other particles, 
such as ZnO and CuO nanoparticles, the presence of serum in the cell culture 
medium did not affect the toxicity to the same extent as for the silica 
nanoparticles199,202. This is potentially due to differences in the toxic mechanisms, 
which for ZnO and CuO nanoparticles are more dependent on the release of ions. 
 
 
 
 
Figure 20. Biocompatibility of nonporous (NSP) and mesoporous (MSP) amine-modified silica 
nanoparticles in MCF-7 cells. A) Cell viability assessed by MTT analysis after exposure to NSP and 
MSP complexed with plasmid DNA (pDNA) in the absence of serum and B) in the presence of serum. 
C) CFE after exposure to NSP and MSP alone, in the absence of serum and D) in the presence of 
serum. n=3 
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In conclusion, the amine-modified silica nanoparticles showed good biocompatibility 
in the MCF-7 cells. The gene delivery efficiency was higher for the nonporous silica 
nanoparticles compared to the mesoporous particles. The presence of serum in the 
cell medium increased the delivery efficiency for the nonporous silica particles, as 
well as abolished the toxic effects for both particles. The results suggest that silica 
nanoparticles are promising as delivery vectors in vivo. However, further 
investigation is required to significantly improve the delivery efficiency as well as to 
understand the cellular uptake mechanisms. 
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9 SUMMARY AND CONCLUSIONS 
Reactive oxygen species (ROS) are involved in several important redox reactions in 
cells and organisms. Concomitantly, ROS also have the potential to damage cellular 
macromolecules, potentially leading to disease development and ageing. A balance 
between the oxidative processes and antioxidative defence is necessary to allow the 
important cellular redox reactions to take place, and at the same time limit the 
oxidative damage to cellular macromolecules. 
 
Chronic kidney disease (CKD) is associated with high levels of oxidative stress, as 
well as inflammation and malnutrition, which all contribute to the higher risk for 
cardiovascular disease in this patient group. In addition to the uraemia, factors 
including dialysis treatment, anaemia, medication, vitamin deficiency and diet, 
influence the oxidative stress level. Moreover, CKD patients also often suffer from 
impaired oral health. Higher levels of DNA damage have previously been reported in 
peripheral blood mononuclear cells (PBMC) in this patient group. However no 
previous studies on DNA damage and oxidative DNA damage in the salivary glands 
in this patient group have been found in the literature.  
 
The aim of Study I was to investigate the levels of oxidative stress and DNA damage 
in minor salivary glands, as well as to assess the levels of saliva production, 
inflammation and uremic markers in CKD patients. In summary, the results showed 
that the levels of DNA damage in predialysis patients were higher compared to 
controls. Despite the observed increased levels of inflammation and uremic markers, 
the levels of DNA damage in the dialysis patients were lower compared to the 
controls. The oxidative DNA damage did not differ between the groups. As expected, 
the saliva production was lower in the CKD patients compared to the controls. The 
results suggest that peripheral tissue and the circulating blood cells are differently 
affected by kidney disease and dialysis, potentially due to upregulated antioxidative 
defence and DNA repair mechanisms induced by the dialysis treatment. 
 
Supplementation with dietary vitamins and antioxidants is an attractive approach to 
decrease levels of oxidative stress and prevent disease. However, intervention studies 
have often failed in showing beneficial health effects of dietary supplementation, 
with some studies even demonstrating adverse health effects. The aim of Study II 
was to investigate the effects of a dietary supplement rich in antioxidants and fatty 
acids (a sea buckthorn extract) on DNA damage, oral health and inflammation in 
dialysis patients. The crossover study (2 × 8 weeks) showed that the supplementation 
did not have any effects on the DNA damage, oxidative DNA damage, inflammation 
or saliva production in the dialysis patients. The results add to the inconsistency and 
contradictions of the beneficial health effects of dietary supplementation. 
 
Exposure to nanoparticles can potentially induce oxidative stress and adverse health 
effects. Nanoparticles exert properties attractive for several applications, e.g. in 
medicine, electronics and inks. Recent advances in nanotechnology bring on an 
increased usage and potentially increased human exposure. The health effects of 
exposure to nanoparticles are not sufficiently understood. Therefore, a further aim of 
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the thesis was to screen a range of particles for their cytotoxicity and to investigate 
the toxicity of selected nanoparticles in different cell types. In summary, Cu- and Zn-
based nanoparticles were particularly cytotoxic and the toxicity varied among 
different cell types. Several nanoparticles, including iron oxide and silica 
nanoparticles, did not induce cytotoxicity. Size-dependent effects were observed for 
Cu and CuO particles, with the nanoparticles being more toxic compared to 
microsized particles.  
 
The aim of Study III was to investigate the toxic mechanisms of Cu-based (Cu and 
CuO) nanoparticles in the human leukemic cell line HL60. In conclusion, Cu 
nanoparticles were more toxic compared to CuO nanoparticles and the Cu ions (from 
CuCl2) at equivalent Cu mass doses. The Cu nanoparticles induced high oxidation in 
an acellular setting, as well as slightly increased levels of intracellular ROS and 
oxidative DNA damage. CuO nanoparticles did not induce acellular ROS and the 
intracellular ROS and DNA damage was limited. Mitochondrial damage was induced 
early in the exposure to Cu nanoparticles, whereas mitochondrial effects of CuO 
nanoparticles and CuCl2 were observed in a later stage, indicating differences in 
toxicity modes. The main type of cell death appeared to be necrosis, however further 
investigations are needed to confirm the cell death type. Differences in the metal 
release processes may explain the different toxicity modes of the Cu and CuO 
nanoparticles. 
 
The aim of Study IV was to study the biocompatibility of amine-modified silica 
nanoparticles and to examine their potential use as vectors for delivery of plasmid 
DNA in a human breast carcinoma cell line (MCF-7). In summary, the gene delivery 
efficiency was higher for the nonporous silica nanoparticles compared to the 
mesoporous particles. The presence of serum in the cell medium increased the 
delivery efficiency, as well as abolished the toxic effects. The results suggest that 
silica nanoparticles are promising as delivery vectors in vivo. However, further 
investigation is required to significantly improve the delivery efficiency as well as for 
increased understanding of the cellular uptake mechanisms. 
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9.1 OUTLOOK 
The oxygen paradox, i.e. that aerobic cells are dependent on oxygen for life, yet 
oxygen is an inherently threat to the cells, is a challenging research field. Oxidative 
stress is associated with several diseases and also ageing. With the aim to decrease 
oxidative stress levels, the interest in dietary supplementation with antioxidants and 
vitamins is great. However, supplementation with antioxidants does seldom affect the 
levels of oxidative stress, as measured with different biomarkers. Further 
investigations on the relationship between endogenous antioxidants and repair 
systems upon increased levels of oxidative stress, caused by either disease or toxic 
agents in the environment, are needed for potential treatment possibilities. Potential 
risk groups or groups that could benefit from dietary supplement would also be 
appealing to identify.  
 
Oxidative stress is also important early in life. New-borns, and especially pre-term 
delivered babies, are more sensitive to oxidative stress. The relationships between 
exposure to oxidative stress early in life and later consequences need further 
investigations. In an on-going collaboration between Karolinska Institutet and 
Karolinska University Hospital, we are investigating the impact of premature birth on 
the levels of oxidative stress and DNA damage in blood cells. 
 
On account of the increased use of nanoparticles in society, there is a great need to 
understand the interactions of nanomaterials with biological systems. Increased 
knowledge of how nanoparticles interact with biological systems is a prerequisite for 
a safe development of nanoproducts including safe and efficient nanomedicine. 
Nanotoxicology and nanomedicine share several challenges and an increased 
understanding of how different physicochemical properties affect the biological fate 
is needed.  Further studies on exposure to nanoparticles as well as biodistribution, 
cellular uptake and toxic mechanisms are required.  
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